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ABSTRACT 
 
Kevin Scott Goudy:  Characterization and Immunomodulation of Regulatory T cells 
in Type 1 Diabetes 
  
“Under the direction of Drs. Roland, Tisch, Stephen H. Clarke, Richard J. Samulski, 
Jeffrey A. Frelinger, and Zhi Liu.” 
 
Type 1 diabetes mellitus (T1D) is a chronic autoimmune disorder characterized 
by the complete destruction of the insulin-producing pancreatic β cells.  The result of β 
cell loss leads to life-long insulin injections in order to maintain blood glucose levels, and 
is associated with both micro-vascular and macro-vascular diseases.  Disease onset is 
related to a genetic predisposition, environmental factors, and a cell-mediated 
immunophenotype.  Previous studies using the non-obese diabetic mouse (NOD) suggest 
that T1D can be prevented by the administration of immunoregulatory proteins that 
induce/expand both antigen specific and antigen non-specific regulatory cells.  The aims 
of the studies described within are to; i.) test the hypothesis that antigen-specific therapies 
can prevent diabetes, and ii) to understand the cause(s) of immunoregulatory T cell 
deficiency in diabetes development.    
 Results from our first study demonstrate that gene therapy with pDNA encoding 
the β cell protein gluatamic acid decarboxyasle 65 (GAD65) via gene gun significantly 
prevents diabetes onset in the NOD mouse.  Diabetes protection was attributed to the 
induction of interleukin-4 secreting immunoregulatory T cells.  We also discovered that 
delivery of the same construct via intra-muscularly injection exacerbated diabetes by the 
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preferentially induction of pathogenic type 1 T effector cells.  Therefore, our findings 
show that the route of delivery of pDNA encoding autoantigens is integral in shaping the 
type of effector cell response. 
 Our second study illustrates that T1D can be regulated by the differential 
expression of the il2 gene located in the Idd3 locus of the NOD mouse genome.  We 
found that reduced IL-2 production by NOD CD4+ T cells resulted in ~two-fold less 
induction of FoxP3-expressing regulatory T cells that are critical for regulating 
autoimmunity.  Furthermore, we described a new role for IL-21 whereby IL-21 
negatively regulates IL-2 production by CD4+ T cells, thus, perpetuating the inhibition of 
regulatory T cells.  Most importantly, we successfully devised an IL-2 therapy regimen 
for NOD mice that overcomes the regulatory T cell deficiency which could lead to a new 
therapeutic approach to prevent and/or treat T1D in humans. 
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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
1.1  Diabetes Classification And Etiology 
 
Diabetes mellitus is a multifactorial set of metabolic diseases caused by insufficient 
insulin production or insulin resistance (www.diabetes.org).  Insulin is a heterodimeric 
protein produced exclusively by the β cells found in the islets of Langerhans in the 
pancreas (1).  The primary function of insulin is to regulate glucose transport and as a 
consequence, glucose metabolism within myocytes and adipocytes (2).  Thus, any 
condition hindering insulin production or retarding insulin action interferes with glucose 
homeostasis. 
 
Type 1 diabetes mellitus (T1D), formerly referred to as juvenile diabetes and 
insulin-dependent diabetes, is a disease characterized by the autoimmune-mediated 
destruction of the insulin-producing pancreatic β cells leading to insulin deficiency 
(www.cdc.gov).  Type 2 diabetes mellitus (T2D), formerly known as adult onset diabetes 
and non-insulin dependent diabetes, results from insulin resistance or insulin secretory 
defects (www.cdc.gov).  Type 3 diabetes mellitus results from factors not involved in 
T1D or T2D, while Type 4 diabetes mellitus refers to gestational diabetes 
(www.diabetes.org). 
 
As noted above, T1D is marked by the autoimmune-mediated destruction of the 
insulin-producing β cells (3, 4).  Clinical manifestations of T1D develop as a result of 
chronic complications related to a hyperglycemic state.  Hyperglycemia develops when 
greater that 80 percent of the insulin-producing β cells have been destroyed (5).  The 
early stages of β cell autoimmunity are characterized by the development of 
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autoantibodies against islet antigens, autoreactive T cells, and an islet cell infiltrate 
referred to as insulitis.  The development of β cell autoimmunity is influenced by both 
genetic and environmental factors (6, 7). 
 
Those afflicted with T1D typically suffer from a number of complications 
associated with inappropriate glucose metabolism, in addition to having a 30% percent 
reduction in life expectancy (www.massgeneral.org/diabetes,org).  Currently, there is no 
cure for T1D.  Pancreatic and islet transplantation is one approach that has been used to 
“cure” T1D.  However, long-term success of these procedures has been limited at best 
due to eventual graft rejection and/or failure.  Currently, the four major obstacles to 
successful pancreas and islet transplantation are ongoing β cell autoimmunity, allogenic 
recognition of the graft, complications associated with immunosuppressive drugs, and 
organ availability.  For instance, established autoimmunity in diabetic patients if not 
suppressed will result in destruction of newly transplanted β cells (8).  Furthermore, 
recipients of allogenic transplants receive potent immunosuppressive drugs, which upon 
long-term use lead to severe side effects.  Current drug therapies for transplant recipients 
include the use of the immunosuppressive drugs FK506 and/or Cyclosporin A that also 
exhibit β cell and kidney cytotoxicity (9).  Finally, the availability of organs is limited as 
the number of donors is few, estimated at 1,200 pancreata in the US per year 
(www.jdrf.org).  Further restricting the availability of the organs is the requirement to 
genetically “match” the graft with the recipient. Despite some promising clinical results, 
pancreatic and islet transplantation is still too premature to be applied large scale for the 
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treatment of diabetic individuals. Thus, in the meantime, Type 1 diabetics remain 
dependent on the use of exogenous insulin therapy. 
 
1.2  The NOD Mouse 
The nonobese diabetic (NOD) mouse, a spontaneous model of human T1D has been 
instrumental for the study of T1D (10).  Eighty and ten percent of female and male NOD 
mice, respectively, develop symptoms that parallel human T1D (11). At three to five 
weeks of age, insulitis is first detected in NOD mice (11).  Insulitis progresses and by 12-
16 weeks of age the majority of β cells are destroyed and hyperglycemic blood levels are 
established (12).  Similar to human T1D, the islet infiltrate is heterogeneous consisting of 
T cells, macrophages, dendritic cells (DC), and B lymphocytes (13).  Additionally, NOD 
mice develop autoantibodies specific for various β cell antigens. Strikingly, several  cell 
specificities targeted by T cells and autoantibodies are shared between NOD mice and 
diabetic individuals. 
 
1.3  Genetic Factors of Type 1 Diabetes 
Since the sequencing and subsequent discovery that the human genome encodes over 
30,000 genes, it is clear that finding a singular genetic basis for a disease is a highly 
challenging endeavor.  It is especially complicated for T1D since disease susceptibility is 
polygenic and also influenced by ill-defined environmental factors.  For example, 
monozygotic twin studies have shown on average 33 percent concordance among 
diabetic twins (14). The genetic locus with the strongest association with T1D 
susceptibility and resistance in humans is the human leukocyte antigen region (HLA) (15).  
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HLA molecules are surface glycoproteins that present antigens to the immune system 
(16). HLA class I molecules (A, B or C) bind and present peptides derived from antigens 
to CD8+ T cells (17).  The HLA class II locus encodes three subclasses known as HLA-
DR, DQ and DP, which bind and present peptides that are recognized by CD4+ T cells 
(16).  Among the HLA class II molecules, it has been found that individuals who have 
certain HLA-DR or –DQ alleles have an increased risk of developing T1D (15, 18).   For 
instance, ninety-five percent of individuals with T1D have HLA –DR3 or DR4 or both 
alleles (19). 
 
The NOD mouse has a similar strong association with Major Histocompatibility 
Complex (MHC) locus and T1D susceptibility and resistance (20).  IAg7, the MHC class 
II allele expressed by NOD mice plays a key role in the initiation and progression of T1D 
(21).  The association of IAg7 with T1D is believed to be due to the molecule’s unique 
structure.  Its direct role in T1D has been confirmed by introduction of transgenes 
encoding various IA alleles that prevent or reduce the frequency of  diabetes in transgenic 
NOD mice (22, 23).  Furthermore, substitution of the histidine and/or serine residues at 
6 and 57 on the β chain with a proline and aspartic acid, respectively, significantly 
reduces the frequency of insulitis and prevents diabetes in the corresponding lines of 
transgenic NOD mice (22, 24). Consequently, it has been proposed that the amino acid 
residues at β56 and β57 influence the peptide binding properties of IAg7 (25, 26).  Studies 
have suggested that IAg7 binds to peptides weakly, and/or the surface half-life of IAg7-
peptide complexes are relatively short-lived (25, 27).  Either of these properties may 
skew the T cell repertoire towards β cell-specific reactivity. 
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idd Chromosome Candidate Genes
idd1 17 MHC I &II, TNFα/β, Tap1&2
idd2 9 Insulin
idd3 3 IL-2. IL-21, HIPK1, PTPN8
idd4 11 FADD
idd5.1 1 Caspase8, CD28, CTLA4
idd5.2 1 CD152, ICOS
idd6 6 ? (localized toD18s87)
idd7 7 GALNT3
idd8 14 ? (localized toD6s264)
idd9 4 Jak1, Lck, TnfR2
idd10 3 ? (localized toD10s193)
idd11 4 ? (localized toD14s67)
idd12 14 ? (localized toD6s86)
idd13 2 Β2m
idd14 13 ?
idd15 5 ?
idd16 17 ?
idd17 3 ?
idd18 3 ?
 
Table 1.1.  Identified idd Loci in NOD Mice 
 
 
 
 
In addition to the HLA and 
MHC loci several other genetic loci 
have been identified (Table 1.1 (for 
review see (7)).  These insulin 
dependent diabetes (IDDM/Idd) loci  
largely encode gene products that 
influence the development and/or 
function of immune effector cells.  It 
is believed that these Idd loci 
primarily function as “modifiers” of 
the dominant effects associated with 
the HLA and MHC loci (18). 
 
1.4  Idd3 and the il2 gene 
Among the more than 20 IDDM/idd HLA- and MHC-independent loci, IDDM3/idd3 has 
one of the stronger associations with T1D susceptibility in humans and NOD mice (28).  
For the purpose of the studies discussed throughout this dissertation, I will focus on the 
murine Idd3 locus located on 5’ proximal end of chromosome 3.  The Idd3 locus is of 
keen interest due to studies demonstrating an association with the development of β cell-
specific effector T cells (29, 30).  NOD mice congenic for an Idd3 interval derived from a 
diabetes resistant strain of mice exhibit a markedly reduced incidence and delayed onset 
of T1D (31, 32).  Mapping of idd3 demonstrated that the interval spans 780 kilobases 
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Table 1.2.  Mutated AP-1 Binding Domain -1010 bp 
Upstream of IL-2 Promoter 
 
 Sequence 
Canonical AP-1 Binding motif:  5’-  tgagtCa  -3’ 
NOD        AP-1 Binding site:      5’-  tgagtTa  -3’ 
 
 
 
 
 
(kb) and contains genes that encode a variety of immunoregulatory molecules: IL-2, IL-
21, homeodomain interacting protein kinase 1 (HIPK1), and protein tyrosine phosphotase 
8 (PTPN8) (33).  IL-2 has been the focus of most studies attempting to define the 
candidate gene(s) in Idd3 (34-36).  Podolin et al. first proposed that the function of IL-2 
was altered in NOD mice compared to disease resistant strains such C57BL/6 (B6) mice 
due to differences in glycosylation (33).  However comparative analyses showed no 
differences between NOD versus B6 IL-2 in stimulating T cell proliferation in vitro (33).  
Nevertheless, it is possible that heavily glycosylated NOD IL-2 is less functional in a 
“natural” environment due to stereo-hindrance (37, 38).  Furthermore, binding of IL-2 to 
the trimeric IL-2 receptor (IL-2R; α receptor (CD25), β receptor (CD122), γ receptor 
(CD132)) may be attenuated by the additional N-glycosylated moieties.  Studies 
measuring the binding affinity of NOD versus B6 IL-2 to the trimeric IL-2R would aid in 
ruling out this possibility (37, 38). 
 
A number of single nucleotide polymorphisms (SNPs) have been identified within 
and flanking the il2 gene (39).  SNPs have been widely used to identify polymorphisms 
associated with various disease states, and can affect gene expression and/or protein 
function.  Notably 
a SNP found -
1010 base pairs 
(bp) upstream of 
NOD il2 within a 
conical binding 
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motif for the AP-1 transcriptional factor has significant effects on il2 gene expression 
(See Table 1.2) (40).  This point mutation reduces AP-1 binding and results in a two-fold 
reduction in NOD il2 gene expression.  This finding is consistent with observations made 
by Yamanouchi et al. demonstrating that an approximate two-fold reduction in IL-2 
expression in NOD mice relative to various NOD.idd3 congenic lines correlates with 
increased diabetes incidence (33, 41). 
 
The genetic evidence that idd3 and specifically IL-2 is involved in the 
development of T1D in both humans and NOD mice raises questions regarding the 
impact IL-2 expression has on T1D susceptibility.  IL-2 is known to have broad effects 
on T cell biology.  The activation of T cells via the T cell receptor (TCR) and 
costimulatory molecules results in the production of IL-2 and up regulation of IL-2R.  
The autocrine/paracrine effects of IL-2 on T cells results in cell survival, clonal 
expansion and the differentiation into effector cells (42).  In addition, IL-2 binding of the 
IL-2R initiates a Stat5-dependent signaling cascade that induces CD25 expression that 
leads to a positive feed back loop (43).  IL-2 also alters the immune response by 
increasing the susceptibility of activated T cells to apoptosis following strong TCR 
signaling. The latter, referred to as activation induced cell death (AICD) is in part 
characterized by increased expression by T cells of death-mediating molecules in the Fas 
and tumor necrosis factor pathways (44).  IL-2 also plays a role in the maintenance and 
function of memory CD8+ T cells (45). 
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In the context of autoimmunity, IL-2 serves a key function in establishing and 
maintaining self-tolerance (For review see (46)).  IL-2 knockout mice develop 
autoimmunity including but not limited to T1D (47, 48), while mice deficient in CD25 
have enlarged lymphoid organs in which T and B cells undergo expansion due to defects 
in AICD (47, 49).  Furthermore, anti-CD25 blocking antibodies exacerbate autoimmune 
disease by preventing IL-2-mediated signaling events in T cells (32).  Finally, as noted 
above elevated IL-2 expression in NOD.idd3 congenic mice reduces the frequency of 
T1D (32, 50, 51).  The mechanism by which IL-2 controls autoimmunity is believed to 
include the induction and maintenance of CD4+ T regulatory cells, which will be 
discussed in depth in a later section. 
 
1.5  il21 Another Candidate Gene In Idd3 
Despite some groups believing that il2 is the lone gene accounting for the association of 
Idd3 with T1D, the Idd3 locus also encodes another gene candidate, namely il21 (31, 52).  
IL-21 is a member of the common gamma chain signaling family (IL-2Rγ) of cytokines 
that include IL-2, IL-4, IL-7, IL-9 and IL-15.  The IL-21 receptor (IL-21Rα) and IL-2Rγ 
are expressed on immune cells such as T, B, NK and DC, and have roles in activation, 
proliferation and survival (53).  IL-21 signaling results in activation of the Jak-Stat 
pathway whereby Stat3 is phosphorylated which in turn promotes up regulation of IL-
21Rα expression.  The downstream effects of IL-21 signaling have been controversial.  
IL-21 was once thought to induce the differentiation of CD4+ T cells into T helper 17 
(Th17) cells (54).  More recently, however, stronger evidence indicates that IL-21 
induces differentiation of T follicular helper (Tfh) cells characterized by the production 
 10 
of IL-21 (55, 56).  Tfh cells are recognized for a capacity to control the formation of 
germinal centers and enhance B cell antibody production (57). 
 
IL-21 may affect T1D in multiple ways.  IL-21 is similar to IL-2 in that both are 
abundantly produced by activated CD4+ T cells (41).  Since IL-21 is a key growth factor 
driving CD8+ effector T cell proliferation, this may preferentially expand autoreactive T 
cells in a lymphopenic environment; a condition attributed to NOD mice by some (31, 
58-60).  Additionally, a recent study suggests IL-21 may also have a direct effect on islet 
generation.  Spolski et al. developed a NOD.IL-21Rα-/- knockout mouse in which 
progression of insulitis was reduced, diabetes prevented, and expression of the 
regenerating gene (Reg) in islets increased (61).  This study described a scenario whereby 
IL-21 signaling in islets suppresses the Reg gene that is required for islet generation.  
Finally, IL-21 has known suppressive effects on the generation and function of regulatory 
T cells that are important in controlling self-tolerance (62). 
 
1.6  Thymic Selection and Self-Tolerance in the T cell Compartment 
Autoimmunity occurs when the immune system fails to discriminate between self- and 
foreign-antigens.  T cell self-tolerance is established in the thymus where CD4+CD8+ 
double positive (DP) thymocytes go through an educational process known as positive 
and negative selection.  During positive selection, DP thymocytes bearing a newly 
rearranged TCR encounter antigen in the context of MHC molecules on the surface of 
cortical thymic epithelial cells.  This interaction delivers a “positive” signal promoting 
survival of DP thymocytes and in turn ensures that the expressed TCR is restricted to 
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self-MHC. DP thymocytes which fail to receive a positive signal undergo apoptosis (63). 
Positively-selected DP thymocytes then traffick to the cortico-medullary junction and 
medulla to undergo negative selection (64).  Normally, autoreactive DP thymocytes are 
clonally deleted during negative selection or rendered non-reactive upon subsequent self-
antigen encounter (65).  Deletion of autoreactive DP thymocytes is determined by the 
affinity and avidity of the TCR for peptide/MHC complexes on the surface of medullary 
thymic epithelial cells and/or thymic DC.  DP thymocytes expressing TCR with relatively 
high affinity for peptide/MHC complexes are deleted.  Negative selection of autoreactive 
DP thymocytes is further regulated by the transcription factor AIRE which controls the 
expression of self-antigens by medullary thymic epithelial cells (66, 67).  In the case of 
T1D, studies in NOD mice suggest that the development of pathogenic β cell-specific T 
cells is due to inefficient negative thymic selection which has been at least partially 
attributed to the peptide binding properties of IAg7 (10, 68, 69).  Less is known about the 
negative selection process in the human development of T1D. 
 
1.7  β Cell Autoantigens 
Islets contain glucagon-producing α cells, somatostatin-producing δ cells, pancreatic 
poly-peptide producing (PP) cells in addition to insulin-producing β cells.   However, 
only β cell antigens are targeted in the disease process reflected by the development of β 
cell-specific autoantibodies and T cell reactivity. 
 
Since T cell pathogenesis is critical in T1D, many studies have aimed to identify 
the important β cell antigens responsible for driving the autoreactive T cell response in 
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NOD mice and diabetic patients (46, 70).  Only a select few β cell autoantigens are 
targeted early in the disease process (71).   However, the diabetogenic T cell response is 
amplified as inter and intra-epitope spreading occurs. For example, during the initial 
stages of insulitis in NOD mice CD4+ T cell reactivity specific for insulin B chain and 
glutamic acid decarboxylase 65 (GAD65) (72) are detected, whereas islet-specific 
glucose-6-phosphatase catalytic subunit-related protein (IGRP) and insulin B chain 
appear to be key early targets of CD8+ T cells (73, 74).  T cells with other specificities 
such as IA-2, heat shock protein 60 (HSP60) and dystrophia myotonica kinase are then 
recruited over time (73, 74). 
 
Insulin is an essential autoantigen in the development of T1D.  Insulin is 
expressed exclusively by β cells in response to increased glucose.  It is secreted in a 
zymogenic form as preproinsulin which undergoes two cleavage modifications yielding 
active insulin and the metabolite C-peptide.  Mice express two isoforms of insulin, 
insulin 1 and 2 while humans only express one form.  Thymic expression of proinsulin 2 
is believed to be crucial for inducing self-tolerance to insulin.  Nakayama and colleagues 
demonstrated that insulitis and diabetes are prevented in NOD mice expressing a 
transgene encoding proinsulin 2 in which the IAg7 and H2Kd restricted epitopes had been 
mutated (78). A similar finding was made by Jaeckel and colleagues using a transgenic 
model system expressing insulin and other autoantigens in the thymus of NOD mice (79, 
80).  Tolerance to insulin led to reduced diabetes incidence whereas tolerance to other 
autoantigens had no effect on disease development. 
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GAD is another β cell autoantigen thought to have a key albeit undefined role in T1D.  
GAD is an enzyme with two isoforms GAD65 and GAD67, that catalyzes the synthesis 
of the neurotransmitter β amino butyric acid (GABA) in the central nervous system (81, 
82).  While the role of GAD in catalyzing the synthesis of GABA in the brain is well 
documented, its function in the pancreas is unclear.  Of the two isoforms, it is GAD65 
that is implicated in the pathogenesis of T1D.  In NOD mice, the earliest detectable 
response to islet extracts coincides with detection of GAD65-specific T cell reactivity.  
Furthermore, immunization with plasmid DNA (pDNA) encoding GAD65 exacerbates 
the onset of diabetes in NOD mice, further suggesting a pathogenic role in T1D (85). 
 
1.8  Development of Autoantibodies in T1D 
Autoantibodies appear to have no pathological role in β cell destruction. However, 
detection of β cell-specific autoantibodies has been extensively used to monitor and 
predict the development of overt diabetes in at risk or prediabetic individuals (86).  For 
instance, greater than 90 percent of at risk individuals presenting with autoantibodies 
specific for GAD65, insulin and/or islet protein tyrosine phosphatase (IA-2) develop 
overt diabetes (87).  Furthermore, studies have shown that the probability of developing 
diabetes is also directly proportional to the titer of a given autoantibody. Individuals 
presenting with islet cell cytoplasmic antigen autoantibodies above 20 JDF units have a 
35 percent chance of developing overt diabetes within five years, while those with less 
than 20 JDF units have only a 5 percent chance (86). 
 
1.9  The Role of T cells in the Pathogenesis of T1D 
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T cells are the primary mediators of β cell destruction while B cells, macrophages and 
DC act as APC to drive the immune response in the islets (88-92).  A direct role for T 
cells in β cell destruction was initially shown by depleting T cells via administration of a 
depleting anti-CD3 antibody, and preventing diabetes in NOD mice (93-96).  
Furthermore, NOD mice deficient of T cells develop neither insulitis nor diabetes, and 
diabetes can be adoptively transferred in immunodeficient NOD.scid mice by T cells 
from diabetic NOD donors.  A number of transgenic mouse lines have been established 
expressing TCR specific for β cell autoantigens that further substantiate the critical role 
for T cells in the initiation and progression of β cell autoimmunity (97-100) 
 
The relative contribution CD4+ and CD8+ T cells in the diabetogenic response 
continue to be a controversial topic.  A number of studies suggest that CD4+ T cells are 
necessary for the early and late stages of β cell autoimmunity.  Several groups have 
shown that activated CD4+ T cells alone can transfer diabetes to irradiated NOD or 
NOD.scid recipients (100).   Additionally, depletion of CD4+ T cells in NOD mice via 
anti-CD4 antibody treatment at early and late preclinical stages of T1D prevents diabetes.  
Prevention of diabetes, however, is only detected when young but not older NOD mice 
(>5 weeks of age) are treated with anti-CD8 antibody (12).  Together, these findings 
suggest that CD8+ T cells play an important role in the initiation of  cell autoimmunity. 
 
The autoimmune process of T1D is mediated and regulated by distinct subsets of 
CD4+ T cells that are characterized by the types of cytokines secreted.  For example, type 
1 CD4+ effector T cells are characterized by secretion of interferon gamma (IFNγ) and 
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tumor necrosis factor-α (TNFα), and are the primary mediators of β cell autoimmunity.  
In general, type 1 T effectors are associated with cell-mediated immunity that supports 
macrophage activation, delayed type hypersensitivity responses, and immunoglobulin 
isotype switching to IgG2a (101, 102). In NOD mice, intra-pancreatic levels of mRNA 
and the frequency of IFNγ and TNFα secreting T cells are elevated in diabetic animals (3, 
103-107).  T cells isolated from the blood of diabetic patients typically secrete IFN 
when stimulated with β cell-derived peptides (108). 
 
1.10  The Role of Immunoregulatory T cells in Self-Tolerance and T1D 
Self-tolerance within the T cell compartment is maintained by the frequency and function 
of immunoregulatory T cells.  As alluded to above, T1D in humans and NOD mice is 
attributed to a functional imbalance between β cell-specific CD4+ type 1 and 
immunoregulatory effectors (106, 109).  The first immunoregulatory subset of CD4+ T 
cells to be defined was the Th2 or type 2 effector (110, 111).  Type 2 effector T cells 
typically mediate humoral immunity, are characterized by the dominate production of IL-
4, and to a lesser extent IL-5, IL-10, and IL-13 (112, 113).  IFNγ and IL-4 have reciprocal 
down-regulatory effects on the differentiation of naïve T cells into type 1 or type 2 
effectors.  For example, IFNγ aids in the differentiation of type 1 T effectors, and blocks 
type 2 T cell development (114).  Conversely, IL-4 promotes and inhibits the 
differentiation of type 2 and type 1 T cells, respectively (111). 
 
The functional balance between β cell specific type 1 and type 2 effector T cells 
does not fully explain the immune process involved in T1D.  Studies have shown that 
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T1D requires a prolonged immune reaction against β cells, and possible constant 
activation of cytotoxic cells in order to result in sufficient β cell death causing T1D.  This 
hypothesis is supported by the observation that progression to T1D can take months, 
years, or even decades until clinical manifestations occur.  Areas of great interest that 
may help explain the long pre-diabetes stage is the role T regulatory cells play in 
regulating autoreactive cells.  Several subsets of immunoregulatory T cells with distinct 
phenotypes and mechanisms of action have been identified for their contribution to the 
prevention of diabetes (115). These subsets include: i) Th3 cells, which primarily secrete 
IL-4 and transforming growth factor-β (TGFβ) and are induced via mechanisms of oral 
tolerance (116), ii) T regulatory type 1 cell (Tr1),  which secrete high levels of IL-10 
(117), and iii) “natural” and “adaptive” CD4+CD25+ regulatory cells  which are defined 
by the expression of the transcription factor Forkhead box P3 (FoxP3+Treg) and exhibit 
suppressor function mediated by cell-cell contact and secretion of TGFβ and IL-10 (118).  
More recently, CD8+ T cells exhibiting immunoregulatory function have also been 
identified (119, 120).  For the purpose of this thesis and in view of their potent 
immunoregulatory function, the following discussion will focus primarily on Tr1 cells 
and FoxP3+Treg.  Discussion of other subsets of immunoregulatory T cells can be 
obtained in the following reviews (121, 122). 
 
Similar to type 1 and type 2 effector cells, Tr1 cells differentiate from naïve 
CD4+ T precursors in the presence of the cytokine IL-10.  Tr1 cells are characterized by 
the secretion of high levels of IL-10, low amounts of IL-5, IFNγ, and no IL-2 and IL-4 
production (117)(123).  Not surprisingly, surprisingly the immunoregulatory function of 
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Tr1 cells is mediated by secretion of high levels of IL-10 which has potent suppressive 
effects on both APC and T cells (117). IL-10 blocks the effector function of APC by 
inhibiting up regulation of costimulatory molecules and pro-inflammatory cytokine 
secretion, and directly inhibits IL-2 and TNFαproduction by CD4+ T cells (124). 
Numerous studies have demonstrated that Tr1 cells prevent the development of type 1-
mediated autoimmuity and inflammatory bowel diseases (125-127). 
 
FoxP3+Treg are thought to play a major role in regulating the progression of β cell 
autoimmunity. FoxP3 is a transcription factor that controls the expression of genes 
encoding key suppressor molecules known to inhibit T effector cell activation and 
differentiation.  FoxP3 controls the expression of CTLA-4 and glucocorticoid-induced 
TNF receptor (GITR) which are known to control activation of APC through cell-cell 
contact, and the expression of TGF-β1 and possibly IL-10 which affect both T cells and 
APC (128). 
 
FoxP3 expression is induced in the thymus and periphery to generate “natural” or 
“adaptive” FoxP3+Treg, respectively.  “Natural” FoxP3+Treg are established in the 
thymus upon recognition of self-antigen.  Even though “natural” FoxP3+Treg arise in the 
thymus, their phenotype and function is similar to the peripheral-derived “adaptive” 
FoxP3+Treg.  The frequency of both “natural” and “adaptive” FoxP3+Treg is critical for 
regulation of self tolerance. Notably, the frequency and function of “natural” FoxP3+Treg 
progressively decline with age in female but not male NOD mice (129-131).   In diabetic 
subjects, FoxP3+Treg exhibit a reduced suppressor activity in vitro (132).  Furthermore, 
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the induction of “adaptive” FoxP3+Treg suppresses ongoing β cell autoimmunity in NOD 
mice (133-135). 
 
Defects in FoxP3+Treg maintenance, expansion, induction and function have all 
been cited as potential causes for aberrant FoxP3+Treg immunoregulation in type 1 
diabetics and NOD mice.  Deficiencies in key immunoregulatory molecules necessary for 
maintaining proper development and function of FoxP3+Treg can be partly attributed to 
the genetics of T1D.  As mentioned earlier, IL-2 is a critical molecule for the 
development and maintenance of FoxP3+Treg.  Altered expression and/or function of IL-
2 would be expected to impact FoxP3+Treg (45, 46).  Additionally, the suppressive 
molecule CTLA-4 found on the surface of FoxP3+Treg also map to the diabetes locus 
Idd5 and has been shown to be down-regulated in NOD mice (136). 
 
1.11  Induction of Immunoregulation to Reestablish Self-Tolerance 
The majority of immunotherapies being tested for the prevention and/or treatment of T1D 
have largely focused on reestablishing self-tolerance within the T cell compartment. 
Typical approaches of immunotherapy have included the induction of β cell-specific 
immunoregulatory T cells, blocking T cell co-stimulation, and depletion of T cells (For 
review see (137)).  In general, two approaches have been used to target T cells for the 
purpose of immunotherapy: antigen-independent versus antigen-dependent therapies. 
Antigen-independent immunotherapy has the advantage of tolerizing large numbers of T 
cells. The latter is a key issue at late stages of the diabetogenic response when the 
frequency of pathogenic effector T cells is high. However, antigen-independent 
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immunotherapy fails to discriminate between T cells specific for self versus foreign 
antigens, and in turn may affect the normal function of the immune system. On the other 
hand, antigen-dependent immunotherapy provides a strategy to selectively target 
autoreactive T cells. However, the efficacy of antigen-dependent immunotherapy 
typically wanes at later stages of disease progression. Recently, “combined” 
immunotherapies are being considered and tested to exploit the respective strengths of 
antigen-dependent and –independent approaches 
 
1.12.1  Antigen-Independent Immunotherapy 
A variety of antigen-independent approaches have been investigated attempting to 
modulate the differentiation and/or function of pathogenic  β cell-specific T cells.  One of 
the more common approaches has been continuous administration of anti-inflammatory 
cytokines such as IL-4, IL-10, IL-13 and TGF-β or the use of blocking antibodies to 
proinflammatory cytokines to prevent diabetes in young NOD mice (138-141).  While 
many of these studies have shown promise, the feasibility and efficacy of cytokine 
immunotherapy is significantly diminished when considering the costs and practicality of 
such a therapy.  Accordingly, gene therapy has been used to express various cytokines 
either systemically or in a tissue-specific manner to effectively modulate autoreactive T 
cell responses in NOD mice (142, 143). 
 
Cell-based immunotherapies are a relatively novel approach being tested to treat 
T1D.  This strategy involves in vitro expansion and adoptive transfer of a given type of 
regulatory cell. For example, exploiting the tolerogenic properties of immature DC or DC 
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rendered immature by suppressing the transcription factor NF-κB has shown to induce 
Tr1 and FoxP3+Treg capable of preventing diabetes in NOD mice (144-147).  The use of 
stem cells is another approach currently being tested in clinical trials for immunological 
disorders, such as graft-versus-host disease, that in turn could be applied for the treatment 
of T1D. Mesenchymal stem cells for example, exhibit potent immunomodulatory 
properties that include suppression of T cell proliferation and induction and/or expansion 
of Treg (for review see (148)). 
 
T cell-depleting antibodies specific for CD4, CD8, and CD25 have been used in 
NOD mice and transgenic mouse models of T1D to effectively prevent or induce 
remission of diabetes (12, 149-153).  The most promising antigen-independent 
immunotherapy to date is the administration of anti-CD3 antibody.  Anti-CD3 antibody 
has been used to treat new onset diabetes in NOD mice, and has exhibited some 
therapeutic efficacy in recent diabetic patients.  For example, long-term remission is 
induced in the majority of diabetic NOD mice treated with a nonmitogenic anti-CD3 
antibody.  The anti-CD3 antibody transiently depletes T cells, in addition to inducing 
Treg that mediate suppression in a TGF-β-dependent manner.   Interestingly, these Treg 
appear to be inducing adaptive FoxP3+Treg from naïve CD4+ T cells not due to the 
expansion of existing “natural” Treg.  Promising results have been obtained in recent 
clinical studies assessing the safety and efficacy of anti-CD3 antibody treatment in recent 
onset diabetic individuals.  Herold et al. using a short course of anti-CD3 antibody 
injections within the first 6 weeks of diagnosis showed continued β cell function in the 
majority of patients up to but not beyond an 18 month period.  The potential side effects 
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from such therapy are obvious as any extended period of immunosuppression opens the 
possibility of opportunistic infection.  Despite potential pitfalls, the ability of anti-CD3 
antibody to reestablish protection by clonally deleting β cell-specific, pathogenic T 
effector cells and inducing FoxP3+Treg makes this therapy the strongest candidate to treat 
diabetes from the antigen-independent therapeutic approaches. 
 
1.12.2   Antigen-Dependent Immunotherapy 
The use of self-antigen as a therapy can affect autoreactive T cells in two ways.  First, T 
cells may undergo clonal anergy and/or deletion upon administration of high doses of 
soluble self-antigen (154, 155).   However, inducing anergy/deletion in a limited set of 
clonotypes is only marginally effective when multiple autoantigens are targeted, as seen 
in the late stages of T1D (156, 157).  Secondly, self-antigen vaccination can 
induce/expand immunoregulatory T cells.  This result is attractive as once established, 
immunoregulatory T cells can traffick to the site of inflammation and suppress the 
differentiation and/or activity of pathogenic T effectors in an antigen-independent manner 
via cytokine secretion.  For example, administration of intact GAD65 or a pool of 
GAD65-specific peptides (e.g. p217-236, p290-309) induces GAD65-specific 
immunoregulatory CD4+ T cells in 12 week-old NOD female mice (158, 159). 
Importantly, the extracellular milieu established by GAD65-specific immunoregulatory T 
cells also promotes the development of additional immunoregulatory T cells with distinct 
β cell-specificities to amplify the protective effect (90, 160, 161). 
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Several factors must be considered when devising an immunotherapy to 
effectively induce β cell-specific immunoregulatory T cells. The first is the identity of the 
βcell antigen used for vaccination.  At late stages of disease progression when the 
frequency of pathogenic T cells is high, a sufficient number of immunoregulatory T cells 
is required to reestablish a functional balance between T cells.  Notably, the number of 
immunoregulatory T cells that can be induced is in part determined by the size of the pool 
of naïve T cell precursors for a given antigen.  Thus, it is important to identify a β cell 
antigen for which a relatively high frequency of naïve T precursors exists.  Studies in the 
NOD mouse have highlighted this issue.  For example, diabetes is readily prevented 
when young NOD mice are vaccinated with several β cell autoantigens such as insulin, 
GAD65, and HSP60 (90, 160, 162-164).  However, in older NOD mice in which β cell 
autoimmunity is well established, only administration of intact GAD65 or its derived 
peptides has consistently induced a sufficient frequency of immunoregulatory T cells to 
prevent diabetes (90, 158, 159, 165).  A possible explanation as to why GAD65 treatment 
works in older mice may partly be explained by a relatively high frequency of GAD65-
specific naïve T cell precursors (137). 
 
The second critical issue is to establish conditions of autoantigen administration 
that preferentially induce immunoregulatory versus pathogenic effector T cells.  Here the 
major concern is that β cell autoimmunity is exacerbated following antigen vaccination. 
Adjuvants such as complete Freund’s adjuvant or alum have been employed to induce 
antigen-specific type 2 and Tr1-like cells at a high frequency (166, 167).  Similarly, the 
co-administration of antigen and anti-inflammatory cytokines such as IL-4 and/or IL-10 
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provides the means to preferentially induce specific subsets of immunoregulatory T cells 
(85, 168, 169).   Tolergenic DC can also be utilized as an adjuvant. Treatment of murine 
or human immature DC with 1α,25-dihydroxyvitamin D3 and/or dexamethasone blocks 
secretion of proinflammatory cytokines and promotes IL-10 secretion upon DC activation. 
Accordingly, adoptive transfer of tolergenic DC pulsed with β cell-derived peptide may 
prove to be an effective approach to elicit peptide-specific Tr1-like cells and/or Treg. 
 
The route of administration is also a key factor in determining the nature of the 
immune response induced by β cell antigen vaccination. For instance, targeting mucosal 
tissues by intranasal or oral administration of insulin and insulin peptides results in 
preferential induction of type 2 effectors or FoxP3+Treg reactivity and diabetes 
prevention in NOD mice (170, 171).  Furthermore, ingestion of transgenic plants 
expressing autoantigens such as GAD67 has also been effective at preventing diabetes in 
NOD mice (172, 173).  However, oral administration of insulin to prediabetic individuals 
in the Diabetes Prevention Trial-1 (DPT-1) showed no significant effect on the 
development of diabetes or reduction in β cell autoimmunity (174, 175).  Although it is 
unclear why the treatment failed to prevent diabetes, administration of insufficient doses 
of insulin is thought to be a likely factor (137). 
 
The final parameter of antigen-specific immunotherapy that needs to be 
considered is the type of immunoregulatory T cells elicited by a given strategy.   
Induction of different types of immunoregulatory T cells, which exhibit distinct modes of 
action would be expected to enhance overall immunotherapeutic efficacy.  For instance, 
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vaccination with pDNA encoding GAD65, IL-4 and IL-10 induces protection for 
syngeneic islet grafts in diabetic NOD recipients (176).  Long-term islet graft protection 
is due to increased numbers of GAD65-specific type 2 effector cells, Tr1 cells and 
FoxP3+Treg.  In contrast, islet grafts are readily destroyed in recipients treated with 
pDNA encoding GAD65 and IL-4 in which only GAD65-specific type 2 effector cells are 
established. 
 
1.13  Aims of the Dissertation 
The objective of the first project is to establish a clinically amenable method of 
preventing T1D. The goal here is to determine whether gene-gun delivery enhances the 
immunotherapeutic efficacy pDNA vaccines. The aim of the second project is to 
elucidate the roles of IL-2 and IL-21 in the development of β cell autoimmunity in NOD 
mice.  In this way a better understanding of the key events driving the diabetogenic 
response can be obtained. 
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2.1  ABSTRACT 
Type 1 diabetes (T1D) is characterized by the T cell mediated destruction of the insulin 
producing β cells. Antigen-specific immunotherapies are used to selectively tolerize β 
cell-specific pathogenic T cells either directly, or indirectly through the induction of 
immunoregulatory T cells. A key concern of antigen-specific immunotherapy is 
exacerbating autoimmunity. We compared the T cell reactivity and efficacy induced by 
plasmid DNA (pDNA) encoding glutamic acid decarboxylase 65 (GAD65) administered 
via intramuscular versus gene gun vaccination in NOD mice at a late preclinical stage of 
T1D. Whereas intramuscular injection of pGAD65 promoted a predominant type 1 CD4+ 
T cell response and failed to suppress ongoing β cell autoimmunity, gene gun vaccination 
preferentially induced IL-4 secreting CD4+ T cells and significantly delayed the onset of 
diabetes.  These findings demonstrate that gene gun delivery of autoantigen-encoding 
pDNA preferentially elicits immunoregulatory T cells and offers a safe, effective strategy 
of pDNA vaccination for the treatment of T1D and other autoimmune diseases.  
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2.2  INTRODUCTION 
Type 1 diabetes (T1D) is caused by the autoimmune-mediated destruction of the insulin-
producing β cells of the islets of Langerhans  .  Based on studies in the nonobese diabetic 
(NOD) mouse, a spontaneous model of T1D, the primary effectors of β cell destruction 
are CD4+ and CD8+ T cells (1). Pathogenic effector T cells typically exhibit a type 1 
phenotype, and target a number of β cell autoantigens including proinsulin, insulin, islet-
specific glucose-6-phosphatase catalytic subunit related protein (IGRP), and glutamic 
acid decarboxylase 65 (GAD65) .  The critical events associated with the development 
and expansion of these type 1 β cell-specific effector T cells remain ill-defined, although 
aberrant peripheral tolerance is believed to contribute. For example, insufficient numbers 
of IL-4 secreting type 2 T cells or IL-10 secreting Tr1 cells, and defective development 
and/or function of FoxP3-expressing immunoregulatory T cells (FoxP3+Treg) have been 
reported in NOD mice and diabetic patients .  
 
A variety of immunotherapies have been developed to reestablish the functional 
balance between pathogenic and immunoregulatory T cells and prevent and/or treat T1D.  
Antigen-specific immunotherapy is one such strategy to induce β cell-specific 
immunoregulatory T cells and selectively block the initiation and/or progression of β cell 
autoimmunity . The efficacy of the approach is largely dependent on the frequency of 
immunoregulatory T cells induced upon administration of a given β cell autoantigen 
versus induction and/or expansion of pathogenic T cells. The conditions to preferentially 
elicit immunoregulatory T cells in an antigen-specific manner become more stringent at 
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late preclinical or clinical stages of T1D when β cell autoimmunity is well established (3, 
4).  
 
We and others have successfully used plasmid DNA (pDNA)-based vaccines to 
induce β cell-specific immunoregulatory CD4+ T cells, and in turn prevent and suppress β 
cell autoimmunity in NOD mice (5-14). In general, pDNA offer: i) a relatively facile 
approach for vaccination, overcoming the need to produce and store antigen, and ii) an 
opportunity to readily manipulate the nature of the induced immune response (15). 
Studies using NOD mice have delivered β cell autoantigen-encoding pDNA prepared in 
saline via intramuscular (i.m.) (9, 11-13) and intradermal (i.d.) needle injection (8), or via 
oral administration (8, 14). Typically, effective prevention of diabetes has been 
dependent on co-injection of pDNA encoding anti-inflammatory cytokines such as IL-4 
and/or IL-10, especially once β cell autoimmunity is well established (9, 11-14). Indeed, 
i.m. injection of pDNA encoding antigen-only has had either no immunotherapeutic 
effect or worse, elicited β cell-specific type 1 CD4+ T effectors (12, 13). The current 
study was initiated to determine how the mode of delivery affects the efficacy of pDNA 
to prevent diabetes at a late preclinical stage in NOD mice. Specifically, the nature of the 
T cell response and immunotherapeutic efficacy of pDNA encoding a fragment of murine 
GAD65 fused to human immunoglobulin Fc (pGAD65) administered by i.m. versus gene 
gun vaccination were compared. Gene gun vaccination entails bombardment of the upper 
most layers of the skin with pDNA-coated particles(15, 16). Notably, studies have shown 
that gene gun immunization preferentially induces type 2 T effectors (17, 18). With this 
in mind, we tested the hypothesis that gene gun vaccination of pGAD65-only is more 
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effective at eliciting GAD65-specific immunoregulatory T cells and suppressing ongoing 
β cell autoimmunity than i.m. injection of pGAD65 prepared in saline.      
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2.3  MATERIALS AND METHODS 
Mice  
NOD/LtJ, NOD.il4 tm1Cgn (NOD.IL-4null), and NOD.scid mice were purchased from 
Jackson Laboratory (Bar Harbor, MA) and bred under specific pathogen-free conditions. 
All experiments with mice were approved by the University of North Carolina at Chapel 
Hill Institutional Animal Care and Use Committee.  
 
pDNA vaccination  
pDNA encoding human immunoglobulin Fc (IgFc) fusion molecules consisting of a 
fragment of murine GAD65 (pGAD65) or hen egg lysozyme (pHEL) spanning 
nucleotides 656-1070 and 175-270, respectively, have previously been described [22]. 
pDNA was prepared from DH5α Escherichia coli using a Qiagen endotoxin-free kit 
(Qiagen, Valencia, CA). For i.m. injection, pDNA was resuspended at 1.0 mg/ml in PBS, 
and NOD mice received four i.m. injections of 50 ul (50 µg) of pDNA in each hind 
quadricep muscle over 28 days with an insulin syringe. Biolistic delivery of pDNA was 
carried out using a Helios gene gun (Bio-Rad, Hercules, CA) and 1.6 µM gold particles 
(Bio-Rad).  Gold particles (0.5 mg) were coated with 1 µg of pDNA using 1 mM CaCl2 
and 0.05 mM spermidine (Sigma, St. Louis, MO). The efficiency of coating was assessed 
by eluting pDNA off the gold particles in Tris-EDTA buffer and then quantitating pDNA 
via agarose gel electrophoresis and spectrophotometry (Beckman Coulter, Fullerton, CA). 
NOD mice with shaven abdomens received four shots at 1-week intervals at a helium 
pulse of 425 pounds per square inch. 
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In other experiments pDNA encoding a luciferase gene (pLUC) driven by a 
CMV/CB promoter  was administered via gene gun or i.m. injection as described above.  
In vivo bioluminescence was measured by injecting mice intraperitoneally (i.p.) with 5 
mg of luciferin (Promega, Madison, WI) and using a two-photon Xenogen imaging 
system (Xenogen, Alameda, CA) while mice were under isofluorane anesthesia.  The 
intensity of bioluminescence was measured at the site of injection as the number of 
photons per second per centimeter squared per steradian as determined by the Xenogen 
software and reperesented as relative optic intensity (ROI) units. 
 
GAD65-IgFc ELISA 
Serum levels of GAD65-IgFc were measured using a human IgG ELISA kit as per the 
manufacturer’s recommendations (Bethyl Laboratories, Montgomery, TX). Briefly, the 
capture antibody was incubated for 45 minutes in PBS on a 96-well high-binding plate 
(Corning, Lowell, MA) at room temperature. The plate was blocked with 1% bovine 
serum albumin (BSA)/PBS, washed, and 25 ul of serum diluted 1:3 with 1% bovine 
serum albumin/PBS was added to each well in duplicate. Samples were incubated at 
room temperature for 2 hours followed by washing three times. Detection antibody was 
then added and incubated at room temperature for 1 hour.  The plate was washed and 
developed using substrate A and substrate B (BD Pharmingen, San Francisco, CA); the 
reaction was stopped using 4N phosphoric acid (Sigma, St. Louis, MO).   Optical density 
values were determined at 450 nm wavelength using an ELISA plate reader (Molecular 
Devices, Sunnyvale, CA.)  
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Assessment of diabetes and insulitis  
NOD mice were monitored weekly for the development of glycosuria via Diastix (Ames, 
Elkhart, IN).  Diabetes was diagnosed by 2 consecutive positive measurements over 48 
hours.  Insulitis was assessed by histology.  Pancreata were prepared for histology by 
fixation in neutral buffered formalin followed by paraffin embedding.  A minimum of 
five sections, 90 µm apart, were cut from each block, stained with hematoxylin and eosin 
(H&E), and viewed by light microscopy.  A minimum of 30 islets were scored for each 
animal.  The severity of insulitis was scored as either peri-insulitis (islets surrounded by 
an infiltrate) or intra-insulitis (< or >50% infiltration of the islets).  
 
Flow cytometry 
Antibodies specific for murine CD3 (2c11), CD4 (GK1.5), and CD25 (PC61) (eBiosience, 
San Diego, CA) were used to stain splenocytes, inguinal lymph nodes and pancreatic 
lymph nodes at 1:500 dilution.  Staining with anti-FoxP3 (FJK-16s) and isotype control 
(IgG2a) antibody (eBioscience, San Diego, CA) was done according to manufacturer’s 
recommendations at a 1:400 dilution.  Acquisition of samples was performed on a 3-laser 
Cyan and analyzed using Summit software build 4.3 (DAKO, Ft. Collins, CO). 
 
Peptides  
Peptides were synthesized using standard F-moc chemistry on a Rainin Symphony 
(Rainin Instruments, Woburn, MA) at the peptide synthesis facility of University of North 
Carolina. The purity of the peptides was verified by reverse phase HPLC and mass 
spectroscopy.  
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ELISPOT  
ELISPOT was carried out as previously described [19]. Briefly, ImmunoSpot M200 
plates (Millipore, Billerica, MA) were coated overnight at 4°C with either 2 µg/ml anti-
IL-5,  -IL-10, or -IFNγ and 1 µg/ml anti-IL-4 (BD PharMingen, San Jose, CA) prepared 
in PBS, and then blocked with 1% BSA-PBS for a minimum of 1 hour at room 
temperature. Splenocytes suspensions prepared from individual mice were plated at 1x106 
cells/well.   Inguinal and pancreatic lymph nodes of 5 mice from each treatment group 
were harvested, pooled and cultured overnight in the presence of 4 ng/ml of mIL-2 
(Peprotech, Rocky Hill, NJ) then washed and plated at 2x105 with an equal number of 
irradiated splenocytes.  Peptide was added in duplicate to wells at a final concentration of 
40 µg/ml.  The plates were incubated for 48 hours at 37°C in 5.5% CO2 and then washed. 
Biotinylated anti-IL-4, -IL-5, -IL-10 or -IFNγ (BD PharMingen, San Jose, CA) were 
added at 2 µg/ml, in 1% BSA-PBS and plates incubated overnight at 4°C.  Plates were 
washed and incubated with streptavidin-HRP  (BD PharMingen; 1/1000) for 2 hours at 
room temperature. This was followed by three washes with 0.025% Tween 20-PBS and 
three washes with PBS only. Development solution consisted of 0.8 ml of 3-amino-9-
ethyl-carbazole (Sigma, St. Louis, MO) added to 24 ml of 0.1 M sodium acetate (pH 5.0), 
plus 0.12 ml of 3.0% hydrogen peroxide; 0.2 ml was added per well.  
 
Adoptive transfer 
CD4+ T cells were isolated from splenocytes of gene gun treated NOD and NOD.IL-4null 
female mice using a CD4 enrichment kit (BD Pharmingen, San Jose, CA), and 
resuspended at 20x106/ml in PBS.  In addition, splenocytes were harvested from diabetic 
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NOD female mice, red blood cells lysed and the cells resuspended in PBS at 20x106/ml.  
NOD.scid male mice then received i.p. injections of 8x106 diabetogenic splenocytes 
alone or in combination with 2x106 CD4+ T cells isolated from treated NOD or NOD.IL-
4null donor mice.   
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2.4  RESULTS 
2.4.1  Gene gun or i.m. delivery of pGAD65 yield high systemic levels of transgene 
expression. 
The type of immune response induced by pDNA vaccination is dependent on both the site 
and mode of delivery (10, 15, 16). The first set of experiments was aimed to determine 
the levels and localization of transgene expression of pDNA delivered to the skin via 
gene gun and the muscle via needle injection. Under the gene gun parameters employed, 
the 1.6 µm gold particles were delivered to the dermal layer of the skin (Fig. 1A). To 
initially evaluate the duration and level of transgene expression, pLUC which encodes 
luciferase was delivered once to the abdomen (1 µg) or quadriceps (50 µg) of NOD mice 
via gene gun or i.m. injection, respectively, and bioluminescence measured at the site of 
delivery over a 2 week period. The kinetics of bioluminescence after a single vaccination 
were similar between the 2 treatment groups; luciferase expression was readily detected 
after 24 hours and persisted up to 14 days post-treatment (Fig. 1B). However, despite a 
50-fold difference in the amount of pLUC administered, up to an ~3-fold increase in the 
intensity of bioluminescence was detected in NOD mice receiving pLUC delivered via 
gene gun versus i.m. injection (Fig. 1B).  
 
The serum level of GAD65-IgFc protein in NOD mice receiving pGAD65 via 
gene gun versus i.m. injection was compared. Here, pGAD65 was administered under 
treatment conditions used to prevent diabetes (see below). Namely, NOD mice received a 
total of 4 injections over 4 weeks of: i) 50 µg of pGAD65 delivered i.m. to each 
quadricep, or ii) gold-particles coated with a total of 1 µg of pGAD65 to the abdomen. 
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Note that the treatment protocol for i.m. injection of pGAD65 was established in a 
previous study [22].The concentration of GAD65-IgFc in serum was then measured over 
time by ELISA specific for human IgFc. Significant levels of GAD65-IgFc (e.g. 2-3 
ng/ml) were detected 7 days after the initial treatment in both experimental groups (Fig. 
1C).  Notably, an ~3-fold increase in GAD65-IgFc was detected at later time points in 
NOD mice receiving pGAD65 via gene gun versus i.m. injection (Fig. 1C). Together 
these findings demonstrate that although robust and persistent transgene expression is 
induced by i.m. injected pDNA, gene gun delivered pDNA results in enhanced and more 
efficient transgene expression. 
 
2.4.2  Gene gun but not i.m. delivered pGAD65 prevents diabetes in NOD mice with 
ongoing β cell autoimmunity.  
The immunotherapeutic efficacy of gene gun versus i.m. vaccination of pGAD65 was 
assessed. Ten week-old NOD female mice were treated as above and diabetes monitored 
up to 36 weeks of age. At 10 weeks of age, NOD female mice are typically euglycemic 
yet β cell autoimmunity is well established. The majority of NOD female mice receiving 
control pHEL via gene gun (8/10) and i.m. injection (7/10) or left untreated (9/10) 
developed overt diabetes with no significant difference in the time of diabetes onset (Fig. 
2A). Furthermore, all NOD female mice treated with pGAD65 via i.m. injection (10/10) 
developed diabetes (Fig. 2A). On the other hand, significant protection was detected in 
NOD female mice receiving gene gun delivered pGAD65 versus i.m. injected pGAD65 
or the respective control groups (P< 0.005; Kaplan-Meier Log Rank Test). In addition, a 
significant reduction in the frequency of diabetes was detected in NOD female mice 
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receiving gene gun (5/10) versus i.m. (10/10) delivered pGAD65 (P=0.039; Chi Square) 
(Fig. 2A). Histological analysis of the nondiabetic 36 week-old NOD female mice 
demonstrated that the majority of islets were infiltrated in the pGAD65 gene gun 
delivered group, but that the frequency of “severe” intra-insulitis (e.g. >50% intra-
insulitis) was reduced compared to pHEL gene gun vaccinated or untreated NOD mice 
(Fig. 2B).  No correlation was observed between the serum levels of GAD65-IgFc 
measured over time and protection against diabetes in the NOD female mice treated with 
gene gun delivered pGAD65 (Fig. 2C,D). In summary, these results demonstrate that 
gene gun but not i.m. vaccination of pGAD65 prevents diabetes at a late preclinical stage 
of T1D, and that protection is independent of systemic levels of GAD65-IgFc. 
 
2.4.3  Protection mediated by gene gun delivery of pGAD65 correlates with the 
induction of type 2 GAD65-specific T cells.  
The magnitude and nature of GAD65-specific T cell reactivity elicited by gene gun 
versus i.m. injection of pGAD65 were compared.  Groups of five 10-week old NOD 
female mice were vaccinated with pGAD65 as described above or left untreated, and 3 
weeks after the final treatment the frequency of IL-4, IL-5, IL-10 and IFNγ secreting T 
cells in response to the IAg7-restricted GAD65 peptides spanning amino acid residues 
206-220 (p206), p217-236 (p217) and p290-309 (p290) was measured via ELISPOT. 
These three peptides are the immunodominant epitopes found within the fragment of 
GAD65 encoded by pGAD65. T cell reactivity was assessed in the: i) pancreatic lymph 
nodes (PLN) which drain the pancreas, ii) inguinal lymph nodes (ILN) which drain the 
abdominal site of gene gun delivered pGAD65, and iii) the spleen. A typical type 1-like 
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response was detected in NOD female mice treated i.m. with pGAD65 (Fig. 3). For 
example, a significant increase in the frequency of IFNγ secreting T cells in response to 
the GAD65-specific peptides was detected in the PLN, ILN and spleen of NOD mice 
vaccinated i.m. with pGAD65 versus untreated animals (Fig. 3). However, no significant 
increase in the frequency of IL-4 and IL-5 secreting T cells in the PLN or ILN was 
detected in the pGAD65 i.m. group compared to untreated animals (Fig. 3). Interestingly, 
a small but significant frequency of IL-4 secreting GAD65 peptide-specific T cells was 
also detected in the spleen of the i.m. pGAD65 vaccinated NOD mice; this response, 
however, was markedly reduced compared to NOD mice treated with gene gun  delivered 
pGAD65 (Fig. 3). A predominate type 2-like GAD65 peptide-specific T cell response 
was detected in NOD mice receiving gene gun delivered pGAD65. The frequency of IL-4 
and IL-5 secreting T cells was significantly increased in the PLN, ILN and spleen of the 
pGAD65 gene gun treated group versus pGAD65 i.m. vaccinated and untreated NOD 
mice (Fig. 3). GAD65-specific T cells secreting IFNγ were also induced via gene gun 
delivery of pGAD65, however, the frequency of these type 1 effectors was reduced 
compared to the frequency of IL-4 (and to a lesser extent IL-5) secreting T cells detected 
within a given tissue (Fig. 3). No significant increase was detected in the frequency of 
GAD65 peptide-specific IL-10 secreting T cells relative to medium-only controls in 
either of the pGAD65 treatment groups or in untreated NOD mice, regardless of the 
tissue examined. Furthermore, GAD65-specific T cell reactivity was similar between 
untreated NOD female mice and animals receiving pHEL by gene gun or i.m. delivery 
(data not shown).  
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No significant increase was detected in the frequency of FoxP3-expressing 
CD4+CD25+ T cells residing in the PLN, ILN and spleen of the two pGAD65 treatment 
groups or in untreated NOD mice (Fig. 4). In conclusion, these results demonstrate that 
whereas i.m. injection of pGAD65 induces a type 1-like T cell response, gene gun 
delivery of pGAD65 elicits a predominately type 2-like response marked by a high 
frequency of GAD65 peptide-specific IL-4 secreting T cells.   
 
2.4.4  GAD65-specific IL-4 secreting CD4+ T cells are necessary to mediate the 
protective effect of gene gun delivered pGAD65.  
The above findings suggested that suppression of β cell autoimmunity via gene gun 
delivered pGAD65 was mediated by GAD65-specific CD4+ T cells secreting IL-4. To 
directly examine this possibility, a co-adoptive transfer model of T1D was employed 
exploiting the use of NOD mice lacking IL-4 expression (NOD.IL4null). Here 10 week-
old wild-type NOD or NOD.IL4null female mice received pGAD65 via gene gun. Three 
weeks after the final treatment, CD4+ T cells were isolated from the pGAD65 treatment 
groups, and co-adoptively transferred with diabetogenic splenocytes into groups of 5 
NOD.scid mice.  As demonstrated in Fig. 5, the transfer of diabetes was significantly 
blocked by CD4+ T cells prepared from pGAD65 gene gun vaccinated wild-type NOD 
mice compared to mice receiving diabetogenic splenocytes-only (P<0.0053; Kaplan 
Meier Log Rank Test) (Fig. 5). In contrast, CD4+ T cells prepared from pGAD65 gene 
gun vaccinated NOD.IL4null failed to block the transfer of diabetes; no significant 
difference in the frequency and time of onset of diabetes was detected in this group 
compared to NOD.scid mice receiving diabetogenic splenocytes-only (Fig. 5). These data 
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demonstrate that suppression of β cell autoimmunity by gene gun delivered pGAD65 is 
dependent on GAD65-specific IL-4 secreting CD4+ T cells.  
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2.5  DISCUSSION 
The key finding made in this study is that despite ongoing β cell autoimmunity, gene gun 
delivered pGAD65 preferentially promotes a robust type 2 CD4+ T cell response that 
significantly prevents the development of diabetes in NOD mice. This is in marked 
contrast to i.m. injection of pGAD65 which induced a dominant type 1 GAD65-specific 
CD4+ T cell response and failed to prevent diabetes in 10 week-old NOD female mice.  
 
Our findings are consistent with previous studies demonstrating that antigen-
encoding pDNA delivered via gene gun typically induces type 2 immunity, whereas i.m. 
needle injection of soluble pDNA promotes type 1 immunity (17, 18). Currently, the 
mechanisms which drive these “default” T cell responses remain ill-defined. Interestingly, 
both gene gun and i.m. vaccination of pGAD65 elicited high systemic levels of GAD65-
IgFc protein based on serum levels in treated NOD mice (Fig. 1C).  Although serum 
levels of GAD65Ig were greater in gene gun treated NOD mice, protection did not 
correlate with systemic GAD65-IgFc concentrations (Fig. 2C,D). These observations 
argue that the nature of the T cell response and suppression of β cell autoimmunity are 
largely dependent on the site and mode of pDNA delivery.  Indeed, work by Escher and 
colleagues demonstrated that the onset of diabetes was delayed when 4 week-old NOD 
female mice received i.d. versus i.m. needle injections of  pDNA encoding human 
GAD65 (8). In this study, however, i.d. needle injection failed to induce a significant 
increase in GAD65-specific IL-4 secreting T cells despite the relatively non-stringent 
conditions (e.g. lack of ongoing β cell autoimmunity) (8). Our results in which a 
significant frequency of GAD65-specific type 2 T cell reactivity was induced by gene 
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gun delivery at a late preclinical stage of T1D further underscores the potent effects of 
particle-delivery of pDNA to the skin. The latter in part may be explained by the 
tolergenic properties of epidermal Langerhans cells  that have been transfected by pDNA 
or which have endocytosed the transgene encoded protein. 
 
The increased efficiency of transgene expression detected with gene gun versus 
i.m. vaccination was another parameter favoring the use of particle-mediated delivery of 
pDNA (Fig. 1B,C).  Levels of protein expressed by pLUC or pGAD65 were increased by 
gene gun delivery, despite using 50- to 100-fold less pDNA compared to i.m. injection 
(Fig. 1B,C). This difference is likely attributed to the fact that pDNA coated on particles 
is directly delivered to the cytoplasm and/or nucleus of cells residing in the skin (16). 
Intramuscular vaccination of pDNA in solution results in transfection of cells found at the 
site of injection as well as systemically, but this process is nevertheless relatively 
inefficient. 
 
 Our results contrast findings made by 
Joussemet et al. (19) in which no significant induction of type 2 T effectors or protection 
was observed when 3 week-old NOD female mice were treated with gene gun delivered 
pDNA encoding full-length human GAD65.  The major difference between the respective 
studies is the cellular localization of the pDNA encoded GAD65 protein. Full-length 
GAD65 is intracellularly expressed and presentation of GAD65 epitopes would be 
largely limited to professional antigen presenting cells (APC) residing in the dermal 
region that have been directly transfected. Furthermore, intracellular GAD65 would be 
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preferentially processed and presented via the MHC class I pathway, which would reduce 
the efficiency of CD4+ T cell activation. On the other hand, GAD65-IgFc is secreted by 
the transfected cells so that an increased number of resident APC can endocytose the 
antigen, and preferentially present the GAD65-specific epitopes via the MHC class II 
pathway and efficiently stimulate CD4+ T cells. Indeed, other studies have demonstrated 
that the magnitude and nature of T cell immunity induced by pDNA vaccination is in part 
determined by the cellular localization of the protein (e.g. secreted versus intracellular) 
(20).   
 
Although gene gun delivered pGAD65 proved to be more effective than i.m. 
injection, a significant number of NOD female mice nevertheless developed diabetes (Fig. 
2A). This is likely due to the frequency and/or type of GAD65-specific 
immunoregulatory T cells induced following pGAD65 vaccination. For example, 
effective and long-term suppression of ongoing β cell autoimmunity requires a relatively 
high frequency of diverse subsets of immunoregulatory T effectors . Protection mediated 
by gene gun delivered pGAD65 was dependent and limited to the induction of IL-4 
secreting GAD65-specific CD4+ T cells (Figs. 3, 5). Other types of immunoregulatory T 
cells such as IL-10 secreting Tr1 cells or FoxP3-expressing CD4+CD25+ T cells (Fig. 4) 
were not significantly increased following pGAD65 gene gun vaccination. Accordingly, 
the magnitude and diversity of immunoregulatory T effectors can be effectively enhanced 
by co-immunization with pDNA encoding other β cell autoantigens (e.g. insulin B chain) 
and/or anti-inflammatory cytokines such as IL-4, IL-10 and TGFβ.   
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In summary, this study demonstrates that the route and mode of antigen-specific 
pDNA vaccination are critical parameters for blocking β cell autoimmunity at a late 
preclinical stage of T1D. Importantly, particle-delivered pDNA offers a promising 
approach to enhance the therapeutic efficacy and safety of autoantigen-specific 
vaccination. 
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Figure 2.1  Increased transgene expression detected with gene gun versus i.m. 
delivery of pDNA. (A) Abdominal skin from untreated (left panel) or gene gun-treated 
(right panel) mice was harvested, sectioned and stained with H&E.   Arrows indicate the 
site of 1.6 µM gold particles delivered by the gene gun. (B) Bioluminescence of NOD 
mice treated with pLUC by gene gun or i.m. was measured at the site of injection. (*; 
P≤0.05 comparing i.m. to gene gun using Student’s T test, n=5 per group). (C) Kinetics 
of systemic expression of GAD65-IgFc transgene was assessed in 10 week-old NOD 
female mice treated at days 0, 7, 14, and 21 using gene gun or i.m. delivery; data 
represents the average + SD of n=5 per group. 
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Figure 2.2   pGAD65 delivery via gene gun protects against diabetes.  (A) Groups of 
10 female NOD mice 10 weeks of age received 4 gene gun (GG) treatments of pGAD65 
or pHEL, or 4 i.m. injections of pGAD65 or pHEL or were left untreated.   The treatment 
groups were monitored for diabetes on a weekly basis. ***P=10-4, pGAD65 gene gun 
versus pGAD65 i.m.; **P=0.0053, pGAD65 gene gun versus untreated; *P=0.02, 
pGAD65 gene gun versus pHEL gene gun (Kaplan-Meier Log Rank Test). (B)  The 
frequency of insulitis was assessed via H&E staining of pancreatic sections prepared 
from nondiabetic 36 week-old NOD female mice receiving via gene gun pGAD65 (n=5), 
or pHEL (n=2), or left untreated (n=1); a minimum of 30 islets was examined per mouse. 
(C) Serum levels of GAD65-IgFc were measured from pGAD65 gene gun treated NOD 
female mice in the above experiment. Dashed and solid lines indicate NOD female mice 
that became diabetic or remained diabetes-free during the course of the experiment, 
respectively. (D) The average serum levels of GAD65-IgFc in pGAD65 gene gun treated 
mice depicted in panel C.  
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Figure 2.3   Gene gun induces GAD65-specific type 2 effector cells.  Splenocytes (A), 
ILN (B), and PLN (C) were prepared from NOD female mice treated with pGAD65 
delivered via gene gun (black bar) or  i.m. injection (gray bar) or from untreated NOD 
mice (open bar) and stimulated with 40 µg/ml peptide. The frequency of GAD65 peptide-
specific IL-4, IL-5, and IFN-γ, secreting T cells were measured via ELISPOT and 
statistical significance determined using a one-way ANOVA (*P≤0.05 pGAD65 gene 
gun versus pGAD65 i.m.; **P≤0.05 pGAD65 gene gun versus untreated; +P≤0.05 
pGAD65 i.m. versus pGAD65 gene gun). 
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Figure 2.4   Gene gun and i.m. pGAD65 delivery had no effect on the frequency of 
FoxP3-expressing CD4+CD25+ T cells. The frequency of FoxP3-expressing CD25+ T 
cells was determined by gating on CD3+ and CD4+ T cells found in ILN, popliteal lymph 
nodes (POP), PLN and spleen (SPLN) of NOD female mice treated at 10 weeks of age 
with pGAD65 delivered via gene gun or i.m. injection or left untreated.  
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Figure 2.5   CD4+ T cells from pGAD65 gene gun treated NOD mice prevent 
diabetes in an IL-4 dependent manner. A mixture of diabetogenic splenocytes and 
CD4+ T cells purified from the spleens of wild type NOD or NOD.IL-4null (■) female 
mice treated with gene gun delivered pGAD65 were transferred into groups of 5 
NOD.scid mice (**P< 0.0053, Kaplan Meier Log Rank Test comparing NOD group to 
the NOD.IL-4null group). 
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3.1  ABSTRACT 
 
Type 1 diabetes (T1D) occurs in the non-obese diabetic (NOD) mouse as a result of the 
functional imbalance between FoxP3+ expressing regulatory T cells (FoxP3+Treg) and 
pathogenic type 1 effector T cells specific for β-cell antigens. The insulin-dependent 
diabetes locus 3 (Idd3) of the NOD mouse encodes two key cytokines involved the 
development and maintenance of FoxP3+Treg: interleukin-2 (IL-2) and   interleukin-21 
(IL-21). The current study was initiated to determine the relative role of these two 
cytokines in the pathogenesis of T1D by comparing NOD mice congenic for a disease 
resistant Idd3 interval (NOD.Idd3) with wild-type NOD mice. Relative to NOD.Idd3 
mice, the frequency and absolute numbers of CD62LhighFoxP3+Treg were significantly 
reduced in the pancreatic lymph nodes and islets of NOD female mice. Notably, 
administration of IL-2 to NOD mice elevated the frequency of CD62LhighFoxP3+Treg in 
vivo. Furthermore, the capacity of NOD CD4+ T cells to upregulate FoxP3-expression 
and differentiate into adaptive FoxP3+Treg in vitro was markedly reduced compared 
NOD.Idd3 CD4+ T cells. This limited efficacy to differentiate into adaptive FoxP3+Treg 
by NOD CD4+ T cells was due to reduced IL-2 secretion, in addition to an increased 
sensitivity to the inhibitory effects of IL-21. Taken together these results demonstrate that 
dysregulation of IL-2 production coupled with altered sensitivity to IL-21 by CD4+ T 
cells impair the development and maintenance of FoxP3+Treg in NOD mice. 
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3.2 INTRODUCTION 
 
The hallmark of Type 1 diabetes (T1D) is the T cell mediated destruction of the insulin-
producing β cells in the pancreatic islets (1-3).  Recent studies in humans as well as the 
nonobese diabetic mouse (NOD), a spontaneous model of T1D, implicate the loss of 
function and/or frequency of immunoregulatory T cells as a factor contributing to the 
expansion of β-cell specific, pathogenic type 1 effector T cells (4-6). The primary 
function of regulatory T cells is to inhibit the function of CD4+ and CD8+ T cells 
independent of their activation, proliferative and effector status (7, 8). Several subsets of 
immunoregulatory T cells with distinct phenotypes and effector mechanisms have been 
identified to play a role in controlling T1D (9). These subsets include: i) type 2 T 
effectors which dominantly secrete IL-4, ii) Th3 cells, which primarily secrete IL-4 and 
transforming growth factor-β (TGFβ) (10), iii) Tr1 cells, which secrete high levels of IL-
10 (11), and iv) natural and adaptive CD4+CD25+ T cells which express the transcription 
factor Forkhead box P3 (FoxP3+Treg), and that exhibit suppressor function mediated by 
cell-cell contact and contact-independent mechanisms (12).  
 
FoxP3 +Treg are widely-considered to be the most potent subset of 
immunoregulatory T cells, and as such play a pivotal role in establishing and maintaining 
self-tolerance (13). For example, humans and mice lacking functional FoxP3 protein 
develop a highly aggressive, systemic form of T cell autoimmunity (14-16). One mode 
that FoxP3+Treg suppress T cells is through their constitutive expression of cytotoxic T-
lymphocyte antigen-4 (CTLA-4) and the glucocorticoid-induced TNF receptor (GITR) 
which block necessary co-stimulatory signals needed for T cell activation (17). 
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Additionally, FoxP3+Treg elicit suppression through a bystander effect via TGFβ  and to 
a lesser extent IL-10 expression (13, 18). TGFβ and IL-10 block the effector function of 
antigen presenting cells (APC) by inhibiting upregulation of costimulatory molecules and 
pro-inflammatory cytokine secretion, and by directly inhibiting IFNγ and TNFα 
production by type 1 effector T cells (19).   
 
The phenotype of FoxP3+Treg can be further defined based on CD62L expression.  
For instance, the suppressor function of CD62LhighFoxP3+Treg is superior in vitro and in 
vivo compared to CD62LlowFoxP3+Treg (6, 20, 21). The potent suppressor function of 
CD62LhighFoxP3+Treg is in part due to the secretion of high levels of TGFβ (6).  Notably, 
our group previously showed that the function and frequency of CD62LhiFoxP3+Treg 
decline with age in NOD female mice which in turn is thought to promote β cell 
autoimmunity (6).  Work done by Szanya et al. also indicated that CD62LhighFoxP3+Treg 
from the spleen of NOD mice exhibit an enhanced capacity to prevent diabetes in an 
adoptive transfer model compared to CD62LlowFoxP3+Treg (20).   
 
The critical events that induce and maintain the frequency of 
CD62LhighFoxP3+Treg are currently ill-defined. However, recent studies have 
demonstrated that IL-2 plays a key role in the maintenance of FoxP3+Treg in the 
periphery (22). For example, mice lacking or having reduced expression of the il2 gene 
develop severe, systemic autoimmunity due to the reduction/absence of FoxP3+Treg (23, 
24).  Furthermore, Sakaguchi et al. showed that diabetes is exacerbated in NOD mice 
when treated with a neutralizing antibody specific for IL-2 at an early age (25). Also, IL-
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2 in combination with TGFβ has been shown to be important for the differentiation of 
naïve conventional CD4+ T cells in to adaptive FoxP3+Treg in vitro (26, 27).  
 
Similar to IL-2, IL-21 is a survival factor for resting and activated T cells. The IL-
21 receptor (IL-21R) shares the common γ of the IL-2 receptor (IL-2Rγ) (28-32).  
Furthermore, IL-21 signaling leads to Stat3 phosphorylation that has important 
implications on the differentiation of the proinflammatory T helper 17 (Th17) and T 
follicular cells (Tfh) T cells (33, 34), and enhances IgG production by B cells and the 
class switching from IgG1 to IgG3 (35). Importantly, IL-21 blocks up-regulation of 
FoxP3 expression (36).     
 
Greater than 20 chromosal loci, termed insulin-dependent diabetes (idd) regions, 
have been identified where many candidate genes are known to affect T cell responses 
(37, 38). While no one gene is sufficient for the development of diabetes, the combined 
effects of susceptibility genes influence the progression of β cell autoimmunity (39). One 
of the major gene determinants affecting tolerance in NOD mice is located in the idd3 
locus.  For example, mice congenic for an idd3 interval derived from a diabetes resistant 
strain of mice exhibit a markedly reduced incidence and delayed onset of T1D (40, 41).  
Mapping of idd3 demonstrated that the interval spans 780 kilobases (kb) and contains 
genes that encode a variety of immunoregulatory molecules including the cytokines IL-2 
and IL-21 (42, 43). The NOD Idd3 locus has been associated with reduced IL-2 
expression by T cells due to a SNP found -1010 bp upstream of the il2 affecting the 
binding of the transcription factor AP-1 (44).  Furthermore, attenuated IL-2 production in 
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NOD mice has been proposed to limit the frequency and function of FoxP3+Treg (45, 
46). Moreover, NOD  mice have also been reported to have increased expression of IL-21 
which may promote the expansion of β cell specific pathogenic effector T cells (40).  
Together, these findings suggest that diabetes is regulated impart by an imbalance of IL-2 
and IL-21 expression, which leads to attenuated FoxP3+Treg frequency and/or function 
found in NOD mice. The current study was initiated to further define the role of IL-2 and 
IL-21 in mediating β cell autoimmunity in the NOD mouse. 
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3.3  MATERIAL & METHODS  
Mice  
NOD/LtJ and NOD.scid mice were obtained from The Jackson Laboratory.  NOD.B6c3D 
(NOD.Idd3) mice were a kind gift from Dr. Ed Leiter of The Jackson Laboratory. 
NOD.Idd3 mice were established by introgression of a 0.05 centimorgan (cM) region of 
the Idd3 interval derived from C57BL/6 (B6) mice. All mice were bred and housed under 
pathogen-free conditions. All mouse experiments used in this study were approved by the 
University of North Carolina Animal Use and Care Committee.  
 
Diabetes monitoring and insulitis scoring 
Diabetes was diagnosed by two elevated urine glucose readings (Diastix) over 2 days. 
Pancreata were harvested and treated with formalin for 24 hrs. After fixation, pancreata 
were serial sectioned (90 uM apart) and stained with hemotoxylin and eosin (H&E).  
Severity of insulitis was scored based upon the level of infiltration of the islets (0=no 
infiltration; 1=peri-insulitis, minor infiltration; 2=insulitis <50%, infiltration of islet is 
less than 50%; 3=peri-insulitis, severe infiltration greater than 50%). More than 100 islets 
were scored per group.  
 
Cell harvesting 
Single cell suspensions were prepared from the thymus, pancreatic lymph node (PLN), 
and spleen, and filtered with a 70 um cell strainer. Peripheral blood lymphocytes (PBL) 
were obtained via submandibular puncture (Goldenrod) and collected in Gibson solution 
followed by RBC lysis.  Islet infiltrating cells were isolated by digesting the pancreas 
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with collagenase D (Roche) for 30 mins and culture for 3 hrs in RPMI 1640 (Gibco) 
complete medium containing 10% heat-inactivated fetal-calf serum (FCS), 100 U/ml 
penicillin/streptomycin (Gibco), 50 uM 2-ME (Sigma).  After three rounds of pipeting to 
disrupt islets, cells were washed with PBS and prepared for staining as described below. 
 
Flow cytometric analysis 
Total cells from the respective tissues were stained with a variety of fluorochrome-
conjugated monoclonal antibodies (mAbs) including: anti-CD3 (2C11), anti-CD4 (L3T4), 
anti-CD8 (Ly-2),  anti-CD25 (PC61.5), anti-CD44 (IM7), anti-CD62L (MEL14), anti-
FoxP3 (FJK.16 kit) (eBioscience). Fc receptors were blocked with a 1/200 dilution of rat 
Ig prior to staining. Stained cells were acquired on a Cyan flow cytometer (Beckman-
Coulter) and analyzed using Summit software (Dako).  
 
T cell cultures    
For general cell culture, 2x105 cells were resuspended in RPMI complete medium. 
Stimulation of T cells for cytokine secretion was done using 96-well plates coated with 
varying concentrations of purified anti-CD3 (2C11, eBioscience) and soluble, functional-
grade anti-CD28 at 2 ug/ml (37.51, eBioscience).  To assess IL-2 production after 24 hr 
treatment with IL-21, 200 ng/ml or a titration thereof of murine recombinant IL-21 
(PeproTech) was added to culture.   
 
In vitro suppression assays   
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PLN and spleen CD4+CD25+ T cells were isolated from 16 week-old mice using FACS 
sorting. Treg were sorted into two groups based on their CD62L expression level (high vs. 
low).  Different ratios of Treg were cultured with naïve 5x104 CD4+ T cells from 
NOD.Idd3 mice in 96-well round bottom plates (Costar). The T cells were cultured with 
5x104 irradiated T cell depleted spleen cells NOD.Idd3 and 5 µg/ml anti-CD3 for 3 days. 
Proliferation was measured in triplicate by the incorporation of [3H]thymidine during the 
last 10-12 hr of the co-culture. Plates were harvested on a Beta counter and data is 
presented in counts per million (CPM). 
 
Cell adoptive transfers   
NOD diabetogenic splenocytes (2.5x106) were suspended in PBS and injected i.p. into 8 
week-old NOD.scid male mice alone or in combination with FACS sorted CD4+CD25+ T 
cells (1x105) isolated from the spleen or PLN of NOD or NOD.Idd3 mice.  Mice were 
monitored bi-weekly post-transfer for diabetes as described above.  
 
Isolation of naïve T cells   
Naïve CD4+ T ells were isolated by negative selection to enrich CD4+ cells followed by 
positive selection for CD62L+ cells (Miltnyi).  Briefly, total lymphocytes were incubated 
with biotin-labeled antibody cocktail enriching for CD4+ T cells but depleting 
CD4+CD25+ cells. Enriched CD4+ T cells were then incubated with CD62L-conjugated 
micro-beads and isolated using a magnetic column. 
 
ELISA   
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Supernatant was collected, diluted 1:3 in 1% BSA PBS, and assessed for IL-2 24 hrs post 
stimulation. The anti-IL-2 antibody set (JES6-1 capture antibody and biotinylated JES6-5 
detection antibody; eBioscience) was used at 2 ug/ml on a high-binding ELISA plate 
(Costar).  IL-21 detection in culture supernatant or diluted serum (1:4) was done using 
ELISA (R&D).    
 
In vitro induction of FOXP3+Treg   
Purified, naïve CD4+ T cells (see above for purification description) from NOD or 
NOD.Idd3 mice were plated at 1x106 on a 96-well tissue-culture treated, flat-bottom plate 
(Costar) coated with 2ug/ml of anti-CD3 (2C11, eBioscience) and anti-CD28 (37.51, 
eBioscience) in HL-1 media (Bio-Whittaker).  Medium was supplemented with 100 U/ml 
penicillin/streptomycin (Gibco). Medium was supplemented with human TGF-β1 (5 
ng/ml) (R&D), recombinant murine IL-2 (20 ng/ml) and/or IL-21 (100 ng/ml) 
(PeproTech).  In some experiments functional grade anti-IL-2 (JES6-1, eBioscience) or 
isotype control (eBioscience) was added to the medium.  
 
NOD IL-2 gene cloning  
Using the forward primer 5’-gaagcttcaggcatgtacagcatgcagctc-3’ that includes a HindIII 
restriction site and the reverse primer 5’-gtcgactagttattgagggcttgttgagat-3’ that contains 
an EcoRV restriction site, the il2 gene was amplified from mRNA (Qiagen) of ConA 
(Sigma) stimulated lymphocytes.  After 35 rounds of PCR using 560C as the annealing 
temperature and PFU Turbo (Promega) as the high-fidelity polymerase, the PCR product 
was cloned into the topo-TA vector (Invitrogen).   The il2 gene was sequenced and then 
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cloned into an andeno-assocaited virus (AAV)-Tet-on vector using Sal 1 and EcoRV sites.  
Transgene expression was verified by measuring IL-2 secretion by transfected HEK 293 
cells via ELISA (see methods above).   
 
AAV induction of FoxP3+Treg  
NOD female mice were either vaccinated with 5x1010 viral particles of  AAV-Tet-on IL-
2 virus serotype 1 (AAV1-Tet-on-IL-2) in contra-lateral hind limb muscles using an 
insulin syringe (BD) or left untreated.  After injection, mice were fed chow containing 
200 mg/kg doxycycline (BioServ) for two weeks. Mice were bled weekly for the 
identification of FoxP3-expressing Treg until the end of the experiment.   
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3.4  RESULTS 
3.4.1 Reduced Diabetes and IFNγ secreting T cells in NOD.Idd3 Mice 
To investigate the role of IL-2 and IL-21 in β cell autoimmunity, NOD.Idd3 mice, 
congenic for a 0.05 cM interval derived from the B6 genotype were employed (41). 
Initially, the frequency of diabetes was compared between NOD and NOD.Idd3 female 
mice. As demonstrated in Fig. 1A, a significant reduction in the incidence of diabetes was 
detected in the cohort of NOD.Idd3 versus NOD female mice (p<0.0001). The frequency 
of insulitis was also markedly reduced in pancreata from 16 week-old NOD.Idd3 female 
mice relative to age matched NOD female mice (Fig. 1B&C). These findings demonstrate 
that the frequency of both insulitis and diabetes is reduced in NOD.Idd3 mice.  
 
3.4.2  An Increased Frequency of FoxP3+Treg is Detected in NOD.Idd3 Mice  
FoxP3+Treg play a critical role in maintaining self-tolerance in the periphery. Since IL-2 
is a key regulatory molecule for the induction and maintenance of FoxP3+Treg, the effect 
of the B6 Idd3 interval on the frequency and absolute number of FoxP3+Treg in the 
thymus, blood, spleen and PLN were compared to NOD mice in a temporal manner.  
Interestingly, levels of expression of CD25 by FoxP3+Treg T cells increased with age in 
NOD.Idd3 but not NOD mice (Fig. 2B). Furthermore, a subtle but nevertheless 
significant increase in the frequency of FoxP3+Treg T cells was detected in the blood, 
spleen, and PLN but not the thymus of NOD.Idd3 mice at all ages examined relative to 
NOD mice (Fig 2C).   Most importantly, we found an approximate two-fold increase in 
the frequency of FoxP3+Treg in the islets of NOD.Idd3 versus NOD mice (Fig. 2D). 
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3.4.3 NOD.Idd3 Mice Contain An Increased Frequency and Number of 
CD62LhighFoxP3+Treg  
We and others have shown that CD62L is a marker for the suppressor “status” of  
FoxP3+Treg (6, 20).  Namely CD62LhighFoxP3+Treg exhibit an increased in vitro 
suppressor function compared to CD62LlowFoxP3+Treg. Accordingly, the frequency and 
number of CD62LhighFoxP3+Treg in the PLN of NOD.Idd3 and NOD female mice were 
assessed. As demonstrated in Fig. 3B the frequency of CD4+CD25+FoxP3+CD62Lhigh T 
cells was increased in the PLN of 16 week-old NOD.Idd3 versus NOD female mice. 
Furthermore, an ~2-fold increase in the absolute number of 
CD4+CD25+FoxP3+CD62Lhigh T cells was detected in the spleen and PLN but not the 
thymus of NOD.Idd3 versus NOD female mice regardless of age (Fig. 3C). Similarly, the 
frequency of CD62LhighFoxP3+Treg was increased in the islets of 16 week-old NOD.Idd3 
mice (Fig. 3D).  These results indicate that the frequency and number of 
CD62LhighFoxP3+Treg are increased NOD.Idd3 female mice.  
 
Elevated numbers of CD62LhighFoxP3+Treg in NOD.Idd3 mice would be 
expected to enhance suppression of effector T cells in the respective tissues. To test this 
possibility, an adoptive transfer experiment was carried out. CD4+CD25+ T cells were 
prepared from PLN of 16 week-old NOD.Idd3 or NOD female mice, co-injected with 
splenocytes from diabetic NOD donors into NOD.scid mice, and diabetes monitored. All 
NOD.scid mice receiving diabetogenic splenocytes-alone or a mixture of diabetogenic 
splenocytes plus NOD CD4+CD25+ T cells developed diabetes (Fig. 4A). In contrast, the 
frequency of diabetes was significantly reduced in NOD.scid mice receiving NOD.Idd3 
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CD4+CD25+ T cells plus diabetogenic splenocytes (Fig. 4A). Therefore the pool of 
CD4+CD25+ T cells from NOD.Idd3 mice exhibited an increased suppressor function 
compared to NOD CD4+CD25+ T cells.  
 
To verify that the increased suppressor function of NOD.Idd3 CD4+CD25+ T cells 
was due to quantitative and not qualitative differences within the pool of 
CD62LhighFoxP3+Treg, the suppressor activity of these immunoregulatory effectors was 
tested in vitro. CD4+CD25+CD62Llow and CD4+CD25+CD62Lhigh T cells were sorted via 
flow cytometry from the PLN of 16 week-old NOD.Idd3 and NOD female mice, and then 
cultured at various ratios with naïve CD4+ T cells from the spleen of NOD mice. As 
expected, CD4+CD25+CD62Llow T cells from either NOD.Idd3 or NOD female mice 
failed to suppress proliferation of the stimulated CD4+ T cells (Fig. 4B). On the other 
hand, CD4+CD25+CD62Lhigh T cells effectively suppressed proliferation of the responder 
CD4+ T cells. Importantly, no significant difference in suppressor activity was detected 
between NOD.Idd3 and NOD CD4+CD25+CD62Lhigh T cells (Fig. 4B). Therefore, the 
enhanced suppressor activity in NOD.Idd3 mice is due to an increased number of 
CD4+CD25+CD62Lhigh T cells.  
 
Finally, to assess the impact of increased numbers of FoxP3+Treg on β cell 
autoimmunity, the frequency of CD4+CD25+Foxp3+CD62Lhigh T cells versus IFN-γ 
secreting CD4+ and CD8+ T cells in the islets and PLN of 16 week-old NOD.Idd3 and 
NOD female mice was determined.  The CD62Lhigh Foxp3+Treg ratio was increased in 
the PLN and most notably the islets of NOD.Idd3 versus NOD mice (Fig. 5). These 
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results indicate that in NOD.Idd3 mice the balance between Treg and effector T cells is 
skewed towards CD62LhighFoxP3+Treg.  
 
3.4.4  Impaired IL-2 Production Attenuates NOD FoxP3+Treg Induction 
As noted above IL-2 has been reported to play a key role in the induction and 
maintenance of FoxP3+Treg (25, 47). With this in mind, the level of IL-2 secretion by 
CD4+ T cells was assessed in NOD.Idd3 and NOD mice in a temporal manner. As 
demonstrated in Fig. 6A a 2- to 3-fold reduction in IL-2 secretion was detected in 
stimulated CD4+ T cells isolated from the spleen of NOD versus NOD.Idd3 mice, 
regardless of age. Similar results were obtained for CD4+ T cells from other lymph 
organs including the PLN (data not shown). These results demonstrate that the NOD Idd3 
interval results in decreased IL-2 secretion by CD4+ T cells. 
 
To gain insight into how reduced IL-2 secretion may affect the number of 
FoxP3+Treg in NOD mice, the efficacy of naïve CD4+ T cells from NOD and NOD.Idd3 
mice to induce FoxP3-expression in vitro was compared.  Using culture conditions 
established by the Shevach group (27), naïve CD4+ T cells purified from NOD and 
NOD.Idd3 mice were stimulated with anti-CD3 and -CD28 antibodies and cultured with 
or without TGFβ1.  The frequency of FoxP3-expressing T cells was increased in 
NOD.Idd3 versus NOD CD4+ T cells (Fig. 6B). Increased expression of FoxP3 in 
NOD.Idd3 CD4+ T cells was detected over varying doses of anti-CD3 antibody (Fig. 6C) 
and TGFβ1 (Fig. 6D) stimulation. Notably, an equivalent frequency of FoxP3-expressing 
T cells was observed in NOD.Idd3 and NOD cultures following the addition of 
exogenous IL-2 (Fig. 6B). The latter finding suggested that endogenous IL-2 secretion by 
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NOD CD4+ T cells was limiting the induction of FoxP3 expression. Indeed, addition of a 
neutralizing anti-IL-2 antibody to cultures containing TGFβ1 effectively blocked the 
induction of FoxP3 expression by both NOD.Idd3 and NOD CD4+ T cells (Fig. 6E). 
These observations demonstrate that reduced IL-2 secretion by NOD CD4+ T cells limits 
the induction of adaptive FoxP3+Treg. 
 
3.4.5 The frequency of CD62LhighFoxP3+Treg is Increased In Vivo in NOD mice 
Treated with IL-2  
Since IL-2 secretion is limited in NOD mice, then increasing the level of “endogenous” 
IL-2 would be expected to enhance the frequency of FoxP3+Treg in vivo. To test this 
hypothesis 10 week-old NOD female mice were injected intramuscularly with a 
doxycycline inducible AAV recombinant encoding IL-2 (AAV-Tet-On-IL-2).  No 
difference was detected in the frequency of CD4+CD25+Foxp3+ T cells in AAV-Tet-On-
IL-2 treated but uninduced NOD mice or animals left untreated (Fig. 7A & B). In contrast, 
NOD mice treated with AAV-Tet-On-IL-2 and in which IL-2 transgene expression was 
induced exhibited an increased frequency of CD4+CD25+Foxp3+ in all organs tested, and 
showed a dramatic increase in CD4+CD25+Foxp3+CD62Lhigh T cells in the PLN (Fig. 7). 
These results indicate that IL-2 availability in vivo is a key factor regulating the 
frequency of FoxP3+Treg.  
 
3.4.6  NOD CD4+ T cells Exhibit an Increased Sensitivity to the Inhibitory Effects of 
IL-21  
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The gene encoding IL-21 also resides within the Idd3 interval (28).  Furthermore, recent 
studies have shown that IL-21 inhibits the induction and/or effector function of 
FoxP3+Treg (36, 48). Supplementing cultures with recombinant IL-21 blocked in vitro 
induction of FoxP3 expression by naïve CD4+ T cells prepared from NOD or NOD.Idd3 
mice (Fig. 8A). Accordingly, whether IL-21 contributed to the limited numbers of 
FoxP3+Treg in NOD mice was investigated. Initially, IL-21 production by naïve CD4+ T 
cells from NOD and NOD.Idd3 mice was compared in a temporal manner. No difference 
in the level of IL-21 secretion was detected in cultures established from age matched 
NOD and NOD.Idd3 female mice (Fig. 8B). Furthermore, serum levels of IL-21 (49, 50) 
were similar in 16 week-old NOD and NOD.Idd3 female mice (Fig. 8C). These findings 
indicate that production of IL-21 per se did not differ significantly between NOD and 
NOD.Idd3 mice. 
 
Based on our above findings the level of endogenous IL-2 secretion is critical for 
the induction of adaptive FoxP3+Treg (Figs. 6,7). With this in mind the effect of IL-21 on 
IL-2 secretion by NOD versus NOD.Idd3 naïve CD4+ T cells was investigated. IL-2 
secretion by NOD.Idd3 CD4+ T cells was inhibited by ~60% at the maximum 
concentration of IL-21 tested (200 ng/ml) (Fig. 7D). Strikingly, IL-2 secretion by NOD 
CD4+ T cells was inhibited ~70% with only 50 ng/ml, and ~92% with 200 ng/ml of IL-21 
(Fig. 7D & E). Furthermore, IL-21 reduced the frequency of FoxP3-expressing CD4+ T 
cells in vitro in a dose-dependent manner (Fig. 7F). Taken together these results indicate 
that the level of IL-21 secretion on a per cell basis is not significantly different between 
NOD and NOD.Idd3 CD4+ T cells. However, NOD CD4+ T cells are more sensitive to 
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the inhibitory effects of IL-21, characterized by markedly reduced levels of IL-2 
secretion and a limited capacity to up-regulate FoxP3 expression relative to NOD.Idd3 
CD4+ T cells.  
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3.5 DISCUSION 
FoxP3+Treg have been cited as the most potent immunoregulatory cell capable of 
controlling the induction and expansion of type 1 effector cells that lead to T1D (12). 
Considering the critical role IL-2 plays in induction, expansion, and function of 
FoxP3+Treg, we hypothesized that the NOD.Idd3 protective alleles that encode il2 aides 
in increasing induction and maintenance of the proper balance of immunoregulation. We 
found that the protective Idd3 allele, relative to the NOD allele, enhances the production 
of IL-2 by activated naïve CD4+ T cells that, in turn, induces a greater frequency of 
Foxp3+Treg in the periphery including the islets. Here we show that T1D susceptibility 
correlates with the reduced frequency of the highly suppressive CD62LhighFoxP3+Treg in 
NOD mice. The protective role this has was evident by drastic reduction in diabetes 
incidence in the NOD.Idd3 mice.  We also determined that that increased IL-2 whether 
by allelic production or introduced by gene therapy is sufficient to induce/expand the 
CD62LhighFoxP3+Treg.  
 
The significance of the impaired ability of NOD mice to transcribe IL-2 maybe 
partly attributed to regulatory cytokines such as IL-21. Here we show that NOD naïve 
CD4+ T cells are more sensitive to IL-21 thus suppressing their ability to produce IL-2 
compared CD4+ T cells of NOD.Idd3 mice. The functional consequence of reduced IL-2 
production in the presence of IL-21 is noted as FoxP3 induction is reduced contingent 
upon the IL-21 levels in the culture. We also demonstrated that IL-21 inhibition of IL-2 
can be rescued by the addition of rIL-2 reulting in the increase of FoxP3+Treg.  
Collectively, we show that elevated IL-2 expression either from a protective Idd3 allele 
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or by a gene therapy approach is important for maintaining the functional homeostasis of 
FoxP3+Treg required to suppress autoimmune reactions.  
 
One surprising discovery in this study was the finding that Treg from NOD and 
NOD.Idd3 mice have similar suppressive capabilities.  This finding contests a previous 
report showing that NOD.Idd3 CD4+CD25+ Treg have enhanced suppressive ability 
compared to NOD Treg due to IL-2 expression (51).  The major difference in this study is 
that we evaluated the suppressive ability of 62Lhigh and 62Llow FoxP3+Treg as we 
discovered a major difference in the composition of these populations in PLN.  Once 
separated by expression profiles and cultured at identical ratios the respective strains have 
similar suppressive abilities.  We previously noted the difference in suppressor function 
of 62Lhigh and 62Llow Treg from NOD mice is primarily due to the expression of TGF-β 
(6).   
 
One of the original hypotheses that attribute diabetes susceptibility to the NOD 
Idd3 locus was the multiple SNPs and gylcosylation pattern of the NOD versus C57B/6 
il2 region (42).  Conceivably, differential gylcosylation could lead to attenuated signaling 
and action due to stereohinderance, among other possibilities, that result in reduced Treg 
frequency.  Despite the 9 amino acid difference (located within the first 90bp of 5’ region 
of il2) resulting in higher N-glysocylation of NOD IL-2 there was no functional 
differences noted between these two proteins.  Additionally, the α, β, & γ IL-2 receptor 
binding domains on IL-2 lye outside of the region affected by the SNPs suggesting that 
NOD and C57B/6 have similar functional ability despite their gylcosylation.  Even 
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though SNPs and protein modifications are not likely the cause of the reduced Treg 
formation in this scenario that is not to say that there could be human T1D or other 
automimmne cases where either IL-2 or CD25 proteins are modified at key residues 
resulting similar reduced Treg numbers.   
 
The most logical explanation for the difference in IL-2 levels between NOD and 
NOD.Idd3 is more likely attributable to the upstream binding transcriptional binding 
domains of the IL-2 gene.  Promoter studies have ruled out the possibility that differential 
IL-2 expression is due to the differences attributed to promoters from the respective 
strains (43).  The most likely candidate explaining the difference between the NOD and 
C57B/6 Idd3 region is the finding of multipible SNPs upstream of the IL-2 promoter that 
effect an AP-1 binding site that is (44).  In this study, when the SNPs in the NOD AP-1 
site were changed to C57B/6 sequence, similar levels of expression were restored. 
 
In summary, our results suggest that the effect of impaired expression of IL-2 
governs the size of the FoxP3+Treg pool and ultimately autoimmune diabetes.  By 
identifying IL-2 deficiency as a root cause of diabetes development in the NOD mouse 
we ultimately would like to transfer this knowledge to clinical directed therapy.  Given 
the fact that we were able to overcome the NOD Treg deficiency by both introducing the 
Idd3 locus as well as expression of IL-2 using gene therapy gives us hope that by the 
exclusive use of IL-2 to alter the Treg population we will be able to prevent T1D.  
However, before we move to the clinic we must determine the optimal IL-2 regimen as it 
pertains to the duration, amount, route, and side effects associated with such a treatment.  
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Are attention is now focused on elucidating these measures as well as identify the 
mechanisms by which Tregs in elevated IL-2 environments elicit their effects. 
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Figure 3.1 NOD.Idd3 mice have reduced diabetes and insulitis. A.) Female NOD (■, 
n=20) and NOD.Idd3 (○, n=19) were followed for diabetes incidence, (Kaplan-Meier 
Log Rank Test of NOD to NOD.Idd3; ***, p<0.001). B.) Islets from NOD (n=7) and 
NOD.Idd3 (n=6) mice were scored from H&E stained pancreata (NOD to NOD.Idd3 Chi 
Square analysis; * p<0.05, *** p<0.001). C.) The severity of insulitis was scored based 
upon the level of islet infiltration: 0= no infiltration, 1= peri-insulitis, 2= <50% intra-
insulitis, 3=>50% intra-insulitis.   
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Figure 3.2 NOD.Idd3 mice have a higher frequency of FoxP3+Tregs.  A.) FoxP3+Treg 
were determined by gating on CD3+, CD4+, CD25+ and FoxP3+ using flow cytometery 
B.) The CD25 MFI was determined on FoxP3+Treg from the PLN of 16 week-old NOD 
(open bars, n=10) and NOD.Idd3 females mice (closed bars, n=9) by gating on 
CD3+CD4+FoxP3+ cells (statistical significance of NOD to NOD.Idd3 mice was 
determined using two-way ANOVA; *, p<0.05, **, p<0.01).  C.) FoxP3+Treg frequency 
was measured in female NOD (open bars, n=9-15) and NOD.Idd3 mice (closed bars, 
n=7-16) at 4, 10 and 16 weeks of age for the thymus, spleen and PLN (statistical 
significance of NOD to NOD.Idd3 mice was determined using two-way ANOVA; *, 
p<0.05, **, p<0.01 ***, p<0.001).  D.) The frequency of FoxP3+Treg in islets isolated 
from NOD (n=7) and NOD.Idd3 (n=8) 16 week old female mice (statistical significance 
was determined using Students T test).   
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Figure 3.3  Similar Suppressive Capabilities of NOD and NOD.Idd3 Treg In Vitro.  
A.) CD62L expression on FoxP3+Treg was classified into high versus low expression for 
NOD.Idd3 and NOD mice. B.) The percentage of CD62LhighFoxP3+Treg from the PLN of 
16 week-old NOD (n=17) and NOD.Idd3 (n=14) mice was preformed using the gating 
scheme described in A (statistical significances was determined using Student’s t Test 
(***, p<0.0001)).   C.) Absolute number of FoxP3+Treg was determined by multiplying 
the frequency of CD62LhighFoxP3+Treg by the overall cellularity of the organ.  The 
thymus, spleen and PLN of NOD (open bar, n=9-15) and NOD.Idd3 female mice (closed 
bar, n=7-16) at 4, 10 and 16 weeks of age were evaluated (statistical significance of 
absolute number of NOD to NOD.Idd3 mice was done using two-way ANOVA, (*, 
p<0.05, **, p<0.001, ***, p<0.0005)).  D.) The frequency of CD62LhighFoxP3+Treg 
found in the islets of NOD and NOD.Idd3 mice 16 weeks of age (Student’s t Test (***, 
p<0.0005)). 
 93 
 
 
 
 
 
 
 
Figure 3.4 Comparison of the Suppressor Function of NOD and NOD.Idd3 
FoxP3+Treg. 
A.) Pooled PLN CD4+CD25+ T cells sorted from NOD or NOD.Idd3 16 week-old female 
mice were transferred with diabetogenic splenocytes in to NOD.scid mice; as a control 
diabetogenic splenocytes alone were also transferred.  NOD.scid recipients were followed 
for diabetes (statistical significance of diabetes development between NOD and 
NOD.Idd3 PLN Treg was done by Kaplan-Meier Log Rank Test, (**, p<0.001).  B.) 
Tregs were sorted from the PLN based upon their CD62L profile (open bar, NOD 
CD62Lhigh; gray bar, NOD.Idd3 CD62Lhigh; black bar, NOD CD62Llow; NOD.Idd3 
CD62Llow thatched bar) and cultured with APC, 2µg/ml anti-CD3 and naïve CD4+ T cells.  
This is a representative graph of three individual experiments.  
 
** 
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Figure 3.5  An Increased Ratio of FoxP3+Treg to effector T cells is Detected in 
NOD.Idd3 mice. The ratio of FoxP3+Treg to CD4+ and CD8+ IFN-γ positive type 1 
effectors (Teff) was determined by dividing the frequency of FoxP3+Treg by the 
frequency of IFNγ producing T cells from 16 week-old NOD (n=6) and NOD.Idd3 (n=5) 
female mice.  This ratio was determined for the islets, and PLN (statistical significance 
was determined using Student’s t Test (**, p<0.01; ***, p<0.001)).  
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Figure 3.6  Impaired IL-2 production accounts for reduced FoxP3 expression in 
NOD CD4+ T cells.  A.) Naïve CD4+ T cells from 4, 10 or 16 week old female mice were 
stimulated with varying concentrations of plate-bound anti-CD3 (10, 5, 1, 0.01 µg/ml 
anti-CD3) and soluble anti-CD28.  IL-2 was measured 24 hrs post-stimulation by ELISA 
(statistical significance of NOD IL-2 levels to NOD.Idd3 was done using two-way 
ANOVA, (*, p<0.05; ***, p<0.001)).  B.) Naïve NOD and NOD.Idd3 CD4+ T cells were 
stimulated in the presence of medium alone, TGFβ1, or TGFβ1 and IL-2.  The dot plots 
are representative of greater than five independent experiments; anti-IL-2, isotype control 
or rIL-2 at 20 ng/ml (statistical significance of NOD CD4+ T cells to NOD.Idd3 was done 
using two-way ANOVA, (**, p<0.01; ***, p<0.001)).  C.) Purified naïve CD4+ T cells 
from NOD or NOD.Idd3 mice were stimulated with varying concentrations of plate-
bound anti-CD3 in the presence of 5 ng/ml of hTGF-β1 for 3 days (statistical analysis of 
NOD to NOD.Idd3 mice was determined using two-ANOVA; *, p<0.05; **, p<0.01). D.) 
Naïve CD4+ T cells from NOD or NOD.Idd3 mice were stimulated with varying 
concentrations of TGF-β1 in the presence of 2 µg/ml anti-CD3 and anti-CD28 for 3 days 
(statistical analysis of NOD to NOD.Idd3 mice was determined using two-Anova; *, 
p<0.05; **, p<0.01). E.) Naïve CD4+ T cells were stimulated in the presence of anti-IL-2, 
isotype control or rIL-2 at 20 ng/ml (statistical significance of NOD CD4+ T cells to 
NOD.Idd3 was done using two-way ANOVA, (**, p<0.01; ***, p<0.001).
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Figure  3.7  Over-expression of IL-2 induces FoxP3+Treg.   A.) NOD mice were left 
untreated (n=5) or injected with AAV-Tet-on-IL-2 (n=5) and either given doxycycline 
containing chow for two weeks (induced) or not (uninduced).  Two weeks post-induction 
all mice were bled and cells were stained for CD3, CD4, CD25, and FoxP3. A 
representative flow cytometric plot for each group is shown and the numbers in each dot 
plot represent the average of five mice. B.) After three weeks post-induction the spleen, 
popliteal (6) and PLN of non-injected (open bars), AAV-Tet-on-IL-2 uninduced (gray 
bars) and AAV-Tet-on-IL-2 induced for three weeks (black bars) were evaluated for CD3, 
CD4, CD25, and FoxP3 (statistical significance was done using two-way ANOVA, (**, 
p<0.01; ***, p<0.001). C.) The percentage of CD62Lhigh FoxP3+Treg was determined in 
the PLN of the respective groups (non-injected (●), AAV-Tet-on-IL-2 not induced (■) 
and AAV-Tet-on-IL-2 induced for three weeks (▲) by staining for CD3, CD4, CD25, 
and FoxP3 (statistical significance was done using two-way ANOVA ( ***, p<0.001)). 
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Figure 3.8  NOD CD4+ T cells are more sensitive to the inhibitory effects of IL-21.  
A.) Induction of FoxP3 was assessed for NOD and NOD.Idd3 naïve CD4+ T cells 
cultured with TGF-β alone, TGF-β and IL-21 (100 ng/ml) or TGF-β + IL-21 (100 ng/ml) 
+ IL-2 (20 ng/ml) and stimulated with plate bound anti-CD3 and anti-CD28. The dot 
plots are representative of 3 separate experiments. B.) Naïve CD4+ T cells from 4, 10 or 
16 week old female mice were stimulated with varying concentrations of plate-bound 
anti-CD3 (10, 5, 1, 0.01 µg/ml anti-CD3) and 2 µg/ml soluble anti-CD28, and  IL-21 
measured in supernatants 4 days post stimulation. C.) Systemic IL-21 levels were 
determined by measuring serum from female NOD (□, n=7-10) and NOD.Idd3 (■, n=6-9) 
at 4, 10 and 16 weeks of age by ELISA (statistical significance was determined using 
two-way ANOVA, (*, p<0.05)).  D.) Naïve CD4+ T cells were cultured with plate-bound 
anti-CD3 and varying concentrations of rIL-21, and IL-2 measured from the culture 
supernatants after 24 hrs. E.) The percent inhibition of IL-2 secretion by IL-21 was 
determined by dividing the levels of IL-2 in the presence of IL-21 by IL-2 secretion in the 
absence of IL-21.  F.) The frequency of FoxP3 induction after three days of culture in the 
presence of IL-21. 
4wk 10wk 16wk 
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4.1  Gene Gun Delivered pDNA Induces Type 2 Effectors: How? 
pDNA vaccination is one approach of antigen-specific immunotherapy that has proven to 
be an effective strategy for preventing autoimmunity in experimental models including 
the NOD mouse.   From our studies and those of others, the success of pDNA vaccination 
is highly contingent upon the modality by which pDNA is delivered, the β cell 
autoantigen(s) targeted, and the use of “helper” plasmids to assist in skewing the immune 
reaction.  Here, we established an approach in which pDNA encoding a fragment of 
GAD65 was injected into the epidermal and dermal layers via gene gun, resulting in the 
induction of type 2 immunoregulatory T cells capable of preventing diabetes in NOD 
mice.  Given the fact that not all NOD mice were protected from diabetes underscores the 
necessity for improved treatment conditions before this therapy can be applied to the 
clinic.   
 
A key issue that was not addressed in our study is the mechanism by which gene 
gun delivery of pGAD65 preferentially induces IL-4 secreting immunoregulatory effector 
T cells.  IL-4 is essential for the differentiation of naïve CD4+ T cells into type 2 effector 
T cells in vivo.  How IL-4 induction might occur upon biolistic delivery of pDNA is not 
entirely clear but other studies have noted similar findings to ours (1, 2).  The cellular 
composition of the skin and draining lymph nodes is likely to be a key factor. For 
instance, skin is known to possess “tolerogenic” properties which may in part be due to 
Langerhan DC (3, 4).  Another possibility is that T cell differentiation is in part 
dependent on the quality and/or magnitude of the TCR signaling events.  As described in 
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Chapter 2, GAD65-Ig serum levels are significantly higher in NOD mice treated with 
pGAD65 delivered via gene gun versus i.m. injection.  Thus, it is possible that the 
“strength” of TCR stimulation due to increased antigen availability at the site of pDNA 
injection may also promote a predominant type 2 T cell phenotype.  
  
Additional experiments are needed to address the possible effect of the Ig scaffold 
of the GAD65 recombinant on type 2 T effector cell differentiation. This is of particular 
interest in view of a study by Bach et al. in which gene gun delivery of pDNA encoding 
full-length GAD65 failed to delay or prevent diabetes in NOD mice. The 
immunotherapeutic effect of GAD65-Ig may in part be attributed to Ig binding by Fc 
receptors (FcR) on APC. There are four types of FcR (I-IV) that can either activate or 
suppress APC.  GAD65-Ig binding of inhibitory FcRIIγ receptors may “condition” APC 
to preferentially induce type 2 T effectors.   
 
Defining the key events that promote immunoregulatory T cells will provide 
important insight needed to improve the efficacy of gene gun delivery of pDNA 
vaccination and its possible clinical application.  
 
4.2   A Move Towards IL-2 Therapy? 
A significant effort has gone into identifying the gene(s) residing in Idd3 that is 
associated with diabetes susceptibility. Of particular interest is the il2 gene.  For instance, 
several observations suggest that deficient IL-2 expression leads to ineffective induction 
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and maintenance of “natural” and “adaptive” FoxP3+Treg (5, 6).  However, work by King 
et al. indicates IL-21, another gene residing in the Idd3 locus, enhances homeostatic 
expansion of β cell-specific pathogenic T cells (7).  Our findings indicate that both IL-2 
and IL-21 play integral roles in regulating the balance between FoxP3+Treg and 
pathogenic effector T cells. These results also highlight the complexity associated with 
the control of immunoregulatory “networks” in the periphery. Subtle changes in the level 
of cytokine expression (e.g. IL-2) and/or responses to a given cytokine (e.g. IL-21) 
appear to have marked effects on the progression of autoimmunity. Key questions that 
still need to be addressed include the relative contribution of IL-2 and IL-21 in driving β 
cell autoimmunity, and the “physiological” levels of IL-2 required for “appropriate” 
maintenance and/or induction of FoxP3+Treg. Of particular interest is defining the role of 
IL-2 in the dichotomy that exists between CD62LhighFoxP3+Treg and 
CD62LlowFoxP3+Treg in NOD.Idd3 and NOD mice, respectively. Finally, the effect of 
IL-2 on FoxP3+Treg can be exploited for the purpose of immunotherapy. Recent studies 
ongoing in the laboratory suggest that β cell autoimmunity can be effectively suppressed 
in AAV-Tet-On-IL-2 treated NOD mice after a short course of IL-2 induction.  
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